Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

Low dose ionizing radiation effects on the immune system

Katalin Lumniczky, Nathalie Impens, Gemma Armengol and 6 more

Environment International · 2021 · Review · CC BY

doi:10.1016/j.envint.2020.106212

Abstract

Ionizing radiation interacts with the immune system in many ways with a multiplicity that mirrors the complexity of the immune system itself: namely the need to maintain a delicate balance between different compartments, cells and soluble factors that work collectively to protect, maintain, and restore tissue function in the face of severe challenges including radiation damage. The cytotoxic effects of high dose radiation are less relevant after low dose exposure, where subtle quantitative and functional effects predominate that may go unnoticed until late after exposure or after a second challenge reveals or exacerbates the effects. For example, low doses may permanently alter immune fitness and therefore accelerate immune senescence and pave the way for a wide spectrum of possible pathophysiological events, including early-onset of age-related degenerative disorders and cancer. By contrast, the so called low dose radiation therapy displays beneficial, anti-inflammatory and pain relieving properties in chronic inflammatory and degenerative diseases. In this review, epidemiological, clinical and experimental data regarding the effects of low-dose radiation on the homeostasis and functional integrity of immune cells will be discussed, as will be the role of immune-mediated mechanisms in the systemic manifestation of localized exposures such as inflammatory reactions. The central conclusion is that ionizing radiation fundamentally and durably reshapes the immune system. Further, the importance of discovery of immunological pathways for modifying radiation resilience amongst other research directions in this field is implied.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

The immune system is the body’s main defence mechanism able to distinguish between self and non-self as well as sensing danger. Its main function is to recognize and eliminate different pathogens and damaged or abnormal cells within the body (Fig. 1).

Direct ionizing radiation (IR) effects on the immune system are well-documented and were among the first radiobiological observations made soon after the discovery of X-rays. With the discovery of antibiotics and anti-inflammatory drugs, together with an increased awareness of radiation carcinogenesis the initial enthusiasm to treat infections and benign diseases with radiation subsided for the most part and was replaced with a sole focus on cancer radiotherapy (RT) using doses that can kill cancer cells (i.e. high doses delivered in multiple fractions, generally 2 Gy per daily fraction). As a result, the radiation literature tends to be dominated for the most part by high dose exposure studies with single doses above 1 Gy. Data from radiation oncology patients come with generally well-defined dosimetry and clinical monitoring, but the presence of a tumour is an important confounding factor from an immunological point of view. For instance, many patients receive fractionated local tumor irradiation of up to 74 Gy total dose as part of an extensive combined modality treatment that can include chemotherapy, surgery and/or immunotherapy. Therefore immunological alterations during cancer treatment may not necessarily be due to radiation effects alone. Studies based on high dose IR applied to cancer patients indicated that radiation had immune suppressive properties and this paradigm prevailed in the scientific literature for decades. On the other hand low (below 100 mGy) and intermediate dose (between 100 mGy and 1 Gy) exposure scenarios are much more relevant for the general population as they may have public health consequences. They are also much more difficult to study because toxicity and carcinogenesis are a lot less obvious while other, more subtle functional alterations gain in importance. DNA damage correlates with the dose and the probability of severe direct DNA damage after low doses and dose rates is low, thus other mechanisms may prevail. Within the long time span between exposure and the onset of the clinically apparent pathologies, likely persisting alterations in the functional integrity of the organism as a whole must be present leading to the development of a pathology. Not only the DNA-damage response (DDR) related pathways, but also other, immune-related pathways may contribute to both cancer and non-cancer health outcomes from exposure to IR. Hence, a holistic approach that integrates these multiple mechanisms at all organizational levels is needed to understand the complex response system.

An accumulating amount of scientific evidence based on epidemiological and pre-clinical studies indicate that low dose exposures might directly impact immune functions and - although controversial -, these data indicate that IR may not only be immune suppressive. A comprehensive review of available data on IR effects on the immune system was published in the UNSCEAR 2006 report including both high and low dose effects and highlighted complex functional changes within the immune system in response to radiation. This was the first report released by an international organisation investigating radiation health effects which abandoned the “classical” paradigm that IR is purely immune suppressive. Actually, this report proposes to consider IR as an immunomodulatory agent due to the multitude and sometimes opposing ways it can influence the immune system depending on various parameters such as dose, dose rate, genetic background, age, health status, comorbidities, lifestyle, environmental co-stressors, etc.

This review is part of a collection of papers summarizing discussions of the MELODI workshop on non-cancer effects of low dose IR, organized in Sitges, Spain, 10–12 April 2019. Here we aim to provide an update on low dose IR effects on the human immune system with the goal to summarize what is “known”, what is suspected but still controversial and what is “not yet known” based on existing epidemiological, clinical and pre-clinical data (Table 1).

Human biomonitoring and epidemiological data on low dose radiation-induced immunological changes

Data from genuine epidemiological studies on immune alterations in the context of low dose exposures remain scarce (Table 2). This may be because symptoms of immune-related diseases do not appear in a form or along a time course that can easily be related to radiation exposure apart from the well-known high radiation sensitivity of many resting lymphocytes.

A substantial amount of data is available from different mass casualties implying acute or chronic exposure scenarios. Among the best studied cohorts today are A-bomb survivors and clean-up workers (liquidators) of the Chernobyl nuclear power plant accident, subjected to single dose acute exposure.

A-bomb survivors and Chernobyl clean-up workers cohorts

Data regarding radiation effects on the immune system of A-bomb survivors started to accumulate in the 1980’s and have been periodically updated ever since. The caveat is of course that there may be influences of race and life style factors. Akiyama reported from the Life Span Study on about 120,000 people who had been exposed to an average of 0.16 Gy according to the dosimetry system revised in 1986 (DS86), which includes “non-exposed” controls. Many long-term immune effects were observed that generally suggested a shift in the peripheral lymphocyte balance in favor of B cells with increased serum immunoglobulin (Ig) levels at the expense of cluster of differentiation 3 (CD3) + T cells which were reduced in both numbers and functionality. A dose-dependent drop in naïve CD4+ and CD8+ T lymphocytes was recorded, while memory cells were less affected. That T cell differentiation and development may be permanently altered was suggested by a rise in rare double negative CD4−CD8−, alpha/beta T cells. The appearance and persistence of TCR-mutant T cells was detected mostly in the memory CD4+ T cell compartment in a dose-dependent manner in individuals aged 20 or older at the time of bombing. A relatively robust dose-dependent readout for TCR mutant frequency was suggested after studies on Chernobyl clean-up workers, even at doses of 0.25 Gy. This would suggest the use of TCR mutation as a potential biodosimeter relevant to T cell function.

In many ways, immune changes observed in A-bomb survivors resemble those associated with aging. It was reported that the output of naïve T cells was reduced, the memory T cell pool was expanded while the TCR repertoire became limited, all of which were associated with low grade inflammation that involved myeloid cells known as inflammaging. Doses in the range of 0.005–0.2 Gy drove accelerated thymic involution, which could still be evident 30 years later when the natural, age-related process was well under way if not completed. The frequency and counts of monocytes were dose-dependently increased by radiation exposure and this increase was more pronounced after 60 years showing a possible acceleration of age-dependent clonal haematopoiesis. However, the response to vaccination in elderly atomic bomb survivors seemed not to be impaired by radiation exposure early in life.

The role of IR in promoting accelerated aging was further demonstrated by looking at telomere length in leukocytes of A-bomb survivors. Lustig et al. showed that circulating leukocytes in A-bomb survivors had shorter than expected telomeres, and impaired function, which was dependent on dose and age at exposure. It was more severe in the young than in the elderly, showing a significant dose-dependency in individuals younger than 12-years at exposure. The authors concluded that because this was measurable in the progeny decades later, the initial lesion was the likely source. The association of telomere shortening with circulating biomarkers for aging, such as cytokine production and peripheral blood cell counts were lost in irradiated individuals indicating that radiation effects override those of aging. The authors hypothesized that the resultant functional defects may not necessarily be a disadvantage as myeloid cells may produce fewer inflammatory cytokines, whereas this argument is difficult to make for reduced T cell function. Of special interest to the discussion here might be the observation by Yoshida el al. who showed a biphasic alteration of CD4+ telomere length with irradiation dose: longer telomeres after low dose exposure and progressively decreasing telomere length with doses above 0.5 Gy which correlated with the individual metabolic status.

Further low-dose IR induced quantitative and functional alterations in immune parameters in Chernobyl clean-up workers were reported by Ilienko et al., who investigated cellular immune parameters of 235 individuals exposed to doses between 0.1 and 3500 mSv. They found decreased CD4+/CD8+ ratios and increased Tregs in 56% of the studied clean-up workers, especially in those exposed to low doses. Interestingly, the authors showed that the decrease in the level of B cells and activated T cells correlated with the increase in interleukin (IL)-1β levels in individuals exposed to doses below 100 mSv. Oradovskaia et al. studied a cohort of clean-up workers who developed different malignant diseases and identified typical immune parameter changes in these people 1–3 years before the manifestation of cancer. These changes include reduced CD3+ CD4+ T cell levels, increased CD8+ T cell levels and hence a reduced CD4/CD8 ratio, and a prevalence for natural killer T (NKT) cells over conventional natural killer (NK) cells confirming previous data of increased NKT cells in clean-up workers. Though these markers seem to indicate a risk for cancer development, it is not clear to what extent these alterations were specific for radiation exposed individuals rather than the general population developing cancer at later times.

Environmental or occupational radiation exposures

Other exposure scenarios of interest are long-term chronic exposures affecting either residents living in regions with increased background radiation (natural or human-made) or workers occupationally exposed to radiation. Studies investigating individuals living in Ramsar, Iran at natural high background radioactivity of up to 260 mSv per year showed mild immunological alterations manifested in increased Ig levels (in particular IgE), increased levels of activated CD4+ cells and a tendency towards T helper 2 (Th2) polarization without changes in innate immune parameters (in terms of neutrophil chemotaxis), while results relating to cytogenetic damage in blood lymphocytes were contradictory. Studies investigating residents living in the Yangjian high background radiation area (with cumulative doses up to 249 mSv) showed an increased tendency of both CD4+ and CD8+ T cells in the peripheral blood mononuclear cells (PBMCs), the latter correlating with dose. Moreover, multiple inflammation-related cytokines and blood proteins were significantly increased, such as soluble IL-6 receptor (sIL-6R), interferon (IFN)-γ, monocyte chemoattractant protein-1 (MCP-1) and C-reactive protein (CRP). Chang et al investigated home environments giving off on average 169 mSv gamma radiation from building materials to 196 individuals over 2–13 years. They found a change in lymphocyte subsets in favour of CD8+ T cells while CD4+ T cell numbers and CD4/CD8 ratio negatively correlated with dose when compared to 55 non-exposed close relatives. Despite the fact that the cited studies focused on different immune parameters their conclusions were quite convergent, showing increased activity in the adaptive immune response and the presence of pro-inflammatory factors. A recent study on gene expression profiles of PBMCs from inhabitants of the high level background radioactivity area in Kerala, India found that immune response pathways were among the radiation-affected over-represented pathways.

Immune markers were investigated in people living in radiation-contaminated areas such as around the Mayak nuclear complex, including the Techa River in the Russian Federation. Akleyev et al. showed that the innate immune system, NKT cells, and neutrophils in particular, might be activated by chronic exposure to approx. 0.9 Gy in a dose and dose-rate dependent manner in residents of Techa River. Another study indicated a dose-dependent decrease in the concentration of T helper cells, reduced IFN-γ levels, increased NKT lymphocyte numbers as well as transforming growth factor beta (TGF-β), matrix metalloproteinase 9 (MMP-9), IgA and IgM levels in Mayak workers exposed to external gamma rays with or without internal alpha radiation. Authors concluded that changes detected in the immune parameters of the investigated individuals favoured the maintenance of a chronic inflammatory status, which could contribute to the development of radiation-related late pathologies such as cardiovascular and malignant diseases. Very similar conclusions were reached by Kiselev et al., who reviewed immunological changes in radiation workers at a Siberian chemical complex (over 4000 workers), at the Mayak nuclear facility and at the Chepetsk chemical and metallurgical plant. The common characteristic of these facilities was the presence of a mixed-type exposure (external gamma rays and internal alpha radiation due to incorporated uranium). Importantly, the study recorded not only basic laboratory changes in immune parameters but also clinically relevant symptomatic immune dysfunctions such as infections, allergies, autoimmunity and immunoproliferative diseases and found an increased risk for immune deficiency leading to an infectious syndrome in nuclear industry workers compared to controls. Significantly elevated IgE levels in a certain group of workers in the absence of a relevant allergic anamnesis was also reported, which might indicate a low dose radiation induced imbalance in humoral immunity. Gyuleva et al. basically confirmed most of these findings in Bulgarian nuclear power plant workers with additional details on individual lymphocyte subpopulations and their activation status. Namely, they showed a subtle but significant decrease in the proportion of naïve CD4+62L+ cells, CD4+CD25+ activated/regulator T cells and an increase in activated CD8+CD28+ cytotoxic T cells, along with an increase in NKT cells in persons receiving doses below 200 mSv. Thus, they hypothesised a possible shift from a Th1 to Th2 response at doses above 200 mSv. The main added value of this study compared to the previous ones was that a) it took into account confounding factors such as smoking and alcohol consumption and b) it discussed the influence of aging as another confounding factor on immune parameters, which can overlap with certain changes seen following radiation. Though, they also showed that most of the changes in the measured parameters remained within the normal reference values illustrating the discrete effects of low doses. Other occupational data are from interventional cardiologists, radiologists and radiation workers. These studies generally report exposure doses well below those found in nuclear industry workers mentioned above. At doses of 8.14 ± 7.81 mSv/year for at least 5 years, i.e. below 50 mSv in cumulative dose, drastic fluctuations in circulating immune cells are unlikely to occur, however more subtle changes such as priming the immune system towards stronger Th1 response upon a secondary challenge were reported. Occasional quantitative changes in the cellular and humoral immune system components have been reported even at standard annual dose levels below 3.5 mSv/year with smoking being an important confounder. High variability amongst “normal” individuals is an important limitation, especially as pre-exposure levels are rarely if ever known in immune epidemiological studies. Diurnal rhythm has a pronounced effect that is impossible to control and individual variation in lymphocyte radiosensitivity is also large.

Studies on radiation-exposed children

There is a limited number of studies investigating immune changes in children exposed to chronic low dose exposures. In general, as reviewed in the UNSCEAR 2013 report, children might be more at risk for a number of radiation-induced late effects both of stochastic and deterministic nature. This is true for the incidence of certain tumors such as leukaemias, skin, brain and thyroid cancer as well as deterministic health effects such as cognitive defects, cataracts and thyroid nodules. For this reason and also for the fact that the immune system maturation in children is still ongoing and damage at this state might lead to different consequences in immune function than in adults or older individuals with various degrees of immune senescence, we considered discussing studies of radiation-exposed children separately from those targeting adults. Chronic low dose exposure in children of kindergarden-age can have long-lasting effects on peripheral blood cell counts. Children exposed to 21–85 mSv gamma radiation over a 1–2 year period experienced a drop in total leukocyte and neutrophil counts and an increase in eosinophils that lasted as long as 5–7 years after the end of exposure, with total lymphocyte numbers not affected when compared to children exposed to 2–5 mSv (Chang et al., 1999). Alterations in T cell immunity were detected in children 6–13 year old living within a 40–75 km radius of radiation-contaminated areas around Chernobyl in North Ukraine and exposed to persistent low level radiation. These children had lower CD4 + T cell counts and a shift in the immune balance towards cytotoxic T cell and NK cell subsets especially in vulnerable populations such as those who developed recurrent respiratory problems. The effects were more pronounced at doses above 1 mSv but were also seen below that dose, although confounding factors such as general health status, individual immunogenetic make-up and exposure to pathogens make radiation dose response patterns difficult to ascertain. Though in children with irritable bowel disease living in the Chernobyl contaminated area no association with radiation was found.

The link between childhood radiation exposure and thyroid cancer was firmly established in the aftermath of the Chernobyl accident in 1986, with non-cancer thyroid diseases including autoimmune thyroid disorders emerging a few years after the accident. This was less of a research focus in the A-bomb survivor cohorts, although thyroid pathologies were studied in middle aged adults from the Hiroshima and Nagasaki cohorts who were exposed in utero, with a mean maternal uterine dose of 0.256 Gy (range 0.005 Gy to 1 Gy). It was determined that they had similar risk estimates as those in the Chernobyl study but there was no significant linear dose response for thyroid nodules or autoimmune thyroid disease. Similarly, thyroid nodules tended to be much more prevalent in the radiation-exposed Marshallese population, but without correlating to abnormal thyroid function. A comprehensive review on the initial epidemiological studies is provided by Saenko et al., who concluded that the frequencies of abnormal haematological parameters and thyroid autoimmunity did not correlate with dose. According to long-term studies, the rise in autoantibodies is very common even at lower doses but it can be transient and does not necessarily yield clinical thyroid autoimmune disease or thyroid dysfunction although well-designed long-term investigations are still needed. The disconnection between the rise in autoantibodies and the lack of clinical disease might be due to a radiation damage-driven release of thyroid antigen without subsequent lymphocytic infiltration. One explanation is the possibility of a transient autoimmune reaction. It is also important to consider the dietary iodine uptake. However, determining the association between low dose exposures and their clinical significance in terms of benign thyroid diseases is not without challenges, which include limited sample size, inadequate dose estimates, prevalence in healthy subsets, gender differences and technical problems that relate to the variety of antibodies that can be studied.

Overall, epidemiological studies on long-term low dose irradiation effects on the immune system indicate a) a consensus regarding persistent alterations in CD4+ T cell numbers and function; b) a shift towards humoral immunity; c) contradictory conclusions on cytotoxic CD8+ T cell numbers and innate immunity, most probably with a shift towards activation of certain NK cell compartments; d) limited knowledge on changes in granulocytes; e) likely accelerated immune aging (Table 3). Overall, there are big gaps in our understanding of functional alterations in immune parameters which are of particular interest at this dose range.

Results from the diverse epidemiological or human biomonitoring studies are difficult to compare mainly due to gross heterogeneities in the studied cohorts in terms of age (both in terms of age at exposure and time elapsed from exposure), doses received, irradiation scenarios (acute or chronic, external, internal or mixed exposures), presence of confounding factors (lifestyle, comorbidities, genetic background) and studied endpoints. A major drawback to almost all of these studies is their purely descriptive nature without much effort to link these to specific pathological conditions or diseases. Studies investigating immune alterations in A-bomb survivors suggested a correlation between radiation-induced chronic inflammation and increased incidence of chronic degenerative-type conditions (e.g. cardiovascular diseases, metabolic alterations). The few observations pointing to an increase in the incidence or susceptibility to infections or towards an increased predisposition for autoimmune disorders await confirmation by further studies. So far, it has been difficult to discriminate between immune alterations that are within the normal resilience capacity of an individual versus those that fall outside that range and might link directly to certain diseases. The fact that immune system alterations are part of many if not all pathophysiological processes leading to chronic diseases not traditionally considered as bona fide immune diseases (e.g. heart conditions) only adds further to the complexity of the issue. A meta-analysis of all epidemiological and biomonitoring studies would be useful to evaluate relevant correlations between radiation effects, immune system changes and related health consequences. A better characterisation of the control group and the study design (including the statistical analysis used), categorisation of the measured endpoints and reported health outcomes would help identifying the most informative studies.

Experimental and pre-clinical data on low dose ionizing radiation effects on the immune system

The number of in vitro and in vivo data about low dose IR effects on the immune system is increasing in parallel with a progressively increasing concern of the medical and scientific community regarding long-term biological effects of low doses. These experimental evidences often confirm epidemiological observations and shed light on the mechanisms how IR interacts with the immune system. In the following paragraphs, we will review the most pertinent experimental findings which complement epidemiological data, focusing on the link between basic molecular mechanisms targeted by IR and the immune system, as well as direct low dose effects on quantitative and functional changes in the different immune compartments. Finally, we will present regulation of the inflammatory response as an example of the differential mechanisms and outputs initiated by low-dose versus high-dose irradiation.

Association between DNA damage response and immune response at low doses of radiation

DNA damage is considered a primary consequence of IR and the activation of the DDR pathway is a key factor in determining long-term cell fate after irradiation. IR at low doses already may induce a variety of lesions like double-strand beaks (DSBs) accompanied by single-strand breaks (SSBs) and/or oxidized bases in a bistranded or unistranded form. Manning et al showed increased frequency of micronucleated erythrocytes in the blood of mice treated in vivo with either external low dose X rays or with PET scan associated internal exposure with the radioisotope 18F-FDG. Rothkamm et al reported that quantification of γH2AX foci in the leukocytes of patients subjected to CT scans could reliably estimate the level of radiation exposure. DNA damage after such low doses is not sufficiently severe to induce cells death but can initiate danger signalling. Interestingly, both in vitro and in vivo studies have shown a remarkable persistence of the DSBs (as evidenced by the slow resolution kinetics of γH2AX foci) even after doses in the range of computed tomography (CT) scans, well below 100 mGy. These changes were first detected and extensively studied in fibroblasts but actually more recent investigations showed a similar persistence and delayed repair kinetics of DNA damage in lymphocytes as well. Plenty of evidence suggests a strong crosstalk between DDR activation and inflammatory response triggering primarily innate immune responses also in case of deficient DNA repair or persistent DNA damage. Damaged cells can release a variety of stress or danger signals called damage associated molecular patterns (DAMPs) which act as mediators of innate immune responses. These endogenous molecules released from damaged, stressed or dying cells, in analogy to the pathogen-associated molecular patterns - are recognised by the pattern recognition receptors located within and on innate immune system cells and instigate inflammatory responses. DAMPs can be different cytokines, DNA, RNA, ATP, intra-cellular proteins or protein fragments, etc. It is remarkable, that this feature of stress response is common with variations across organisms of different complexity and evolutionary phylogeny i.e. from plants to mammals.

Systemic and abscopal effects of local radiotherapy

Although typical fraction doses for RT are 2 Gy to the tumor, neighboring tissues can receive a wide range of low to medium doses up to 0.5 Gy. In many cases of RT, biological and clinical systemic immune and inflammatory responses were found to be similar to responses of the irradiated tissues reflected in changes of key modulators of the immune system like cytokines or chemokines. For example, in a study by Mathias et al differential anti- and pro-inflammatory responses were detected in the heart after local heart irradiation with low and high doses and these differential responses were partly reflected at systemic level, in the plasma as well. Several studies in human patients undergoing RT support a time- and treatment-dependent modulation of specific cytokines at systemic level, which in some cases can persist up to several years post-treatment, indicating a definite systemic response to radiation mediated by inflammatory pathways. These systemic phenomena have also been observed in animals as reviewed in. Of course, these excessive immune responses not only contribute to chronic inflammation and tissue damage but also to clearance of damaged cells and tissue remodeling/regeneration.

Thus, local RT can cause changes in tissues and organs outside the field of irradiation. This is called the abscopal effect where it can cause damage to unirradiated normal tissues, or to a distant, non-irradiated tumor. Clinically, such effects are well recognised, as patients often suffer from fatigue, diarrhea and weight loss during local RT. Reports of spontaneous anti-tumour abscopal responses are rare, since an immune tolerant state has already been established in the patient; Abuodeh et al reported 35 cases over 45 years, out of millions of RT patients treated during this period. Since the first report by Demaria et al that the immune system was an integral component of the abscopal response, there have been studies reported, in which activation of the immune system, commonly using checkpoint inhibitors against cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) and OX40 in combination with local RT, was able to induce growth suppression in the second unirradiated primary tumor. On the other hand, under optimal conditions (eg targeting a hypoxic core of the tumour with ablative RT), the anti-tumor effect can be achieved with RT alone. Exposure of blood and normal tissues surrounding the tumor, including the bone marrow and thymus, to low-dose scatter radiation, may play a role in the abscopal effects affecting normal non-irradiated tissues. After both external beam- and radionuclide RT, persistent and statistically significant increased DNA damage was observed in circulating PBMCs, and their repair capacity was affected. This could be explained by protracted induction of DNA damage by abscopal effects in susceptible progenitor cells that is revealed later as increased unrepaired damage in PMBCs.

Low dose radiation induced quantitative and functional changes in immune parameters

Lymphocytes are very sensitive to high dose irradiation. Though, a more in-depth analysis reveals significant differences in the radiosensitivity of the different immune cell subsets even after high doses with B and CD8+ T lymphocytes being more radiosensitive while dendritic cells (DCs), monocytes, macrophages and regulatory T cells being more radioresistant. Radiosensitivity of NK cells is controversial, with some studies reporting that NK cells are more radioresistant than CD3+ cells, while others reporting the opposite.

Low dose radiation elicits a more heterogeneous immune response to radiation. Using murine models, it was shown that single low doses (up to 100 mGy) induced mild and transient (up to 21 days post irradiation) decrease in the pool of all the above mentioned splenic subpopulations. If similar doses were delivered chronically over a period of 1–17 weeks, no changes were detected in the short-term but a long-lasting increase in T and B cell numbers were registered in mice after antigen stimulation. Much lower doses (100 mGy/year) on the other hand did not impact on T or B cell pools, indicating these doses were too low to induce immune effects. TCR repertoire profiling in mice showed that acute low/intermediate exposure could promote premature immune aging called immunosenescence. Exposure to a single dose of radiation was found to accelerate ageing of the peripheral TCR repertoire. The consequences of exposure were already visible after 1 month and lasted for 6 months. Interestingly, they were more pronounced in animals exposed to 0.1 Gy than in those exposed to 1 Gy, where they were partially corrected with time, indicating that they can be reversed/attenuated. Of note, some of these effects were due to radiation-induced impairment of hematopoietic stem cells.

Chronic low dose rate irradiation of mice induced a) stimulation of innate immunity by enhancing the cytotoxicity of pre-stimulated NK cells, b) myeloid cell differentiation and activation, c) suppression of pro-inflammatory responses and d) a shift towards a Th2-type T cell phenotype due in part to radiation-induced gene expression alterations in CD4+ T cells. Low dose effects on DCs are less well characterized. Persa et al. showed that low and high dose acute irradiation induced qualitatively different functional changes in murine splenic DCs in vivo. By this, low doses stimulated antigen uptake and lowered antigen presentation while high doses did not influence these parameters, on the other hand high doses increased the expression of T cell costimulatory markers and enhanced the production of pro-inflammatory cytokines. Other groups performing in vitro irradiation with doses ranging from 0.05 to 5 Gy of DC-precursors or mature DCs stimulated by lipopolysaccharide (LPS) reported no influence of irradiation on surface marker (CD80, CD83, CD86), cytokine expression or the capacity of the DCs to stimulate T-cell proliferation. Moreover, a co-incubation of bone marrow-derived DCs with supernatant of LPS stimulated and irradiated macrophages resulted in a diminished CD40 expression but did not impact on the DC-derived induction of T-cell proliferation.

Toll-like receptors (TLR), appearing on innate immune cells induced DC maturation which primed T-cells. In the presence of costimulatory elements, cytokine release was established which lead to macrophage activation. Low dose fractionated irradiation of mice lead to increased phagocytic activity of macrophages and increased CD8+ T cell cytotoxicity. Another pathway important in radiation response from the immune system is through nucleotide binding oligomerisation domain (NOD)-like receptors. These are inflammasomes, which are important in case of damage from IR or from viruses. The redox status of cells may work as a rheostat, which may lead to a vicious circle of harm in case of excess oxidation, or may calm down the inflammation in reduced conditions. TLR agonists like LPS (especially for TLR4), may influence the response to ionizing radiation.

As previously mentioned, RT can induce long lasting systemic changes in immune/inflammatory parameters. These changes may appear gradually during the course of the treatment, and even further evolve in the weeks following its completion. Hence, the modulation of the expression of some inflammatory (ARG1, BCL2L1, MYC) genes in blood cells was not apparent after the first two fractions but became significant after the 25th in patients treated for endometrial cancer. Of note, RT did not modulate these same genes as strongly in head and neck patients. This difference may be due to different volumes of blood being exposed at each fraction in endometrial and head and neck patients, or to different effects of the different tumour entities on the immune system. The presence of a carcinoma in the head and neck area have indeed been shown to promote an immunosuppressive state in patients, which is even accentuated (increase in Tregs, increased expression of checkpoint molecules on CD4+ T cells), during and after RT. Systemic modulation of cellular and humoral immune parameters can also depend on the mode of radiation delivery. However, most of these studies addressed changes occurring after repeated localized exposure, and it is therefore difficult to assess the exact role of low dose in these observations. Radiation-induced gene expression changes were also investigated in peripheral blood cells of RT-treated prostate cancer patients 18–24 hours after the first fraction (2.09 Gy), resulting in an equivalent total body blood dose of around 31 mGy. Gene set enrichment analysis showed the activation of several pathways involved in immune signaling: IFN secretion, CD28 stimulation, antigen processing and presentation, B-cell receptor (BCR) and TCR activation, inflammasomes, transcription factor nuclear factor kappa B (NF-κB), TLR and cytokine signalling indicating that local high dose resulted in systemic activation of pathways involved in immune processes. Interestingly, the comparison of the response elicited in whole human blood exposed in vitro to 0.05 or 1 Gy suggested that low dose radiation rather induced pro-survival/anti-apoptotic and immune response pathways, whereas high dose exposure rather induced p53-dependent signaling pathways. A similar dichotomy was found for the response to low and high dose radiation of purified human monocytes exposed in vitro. Low, but not high dose exposure induced the transcription of genes involved in TLR signaling, with a concomitant activation of NF-κB, p38, extracellular-signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). In contrast, exposure to 1 Gy induced phosphorylation of p53 and transcription of p53-dependent genes. In vitro exposure of human PBMCs obtained from healthy donors to 0.05 Gy of X rays or 12C ions did not induce significant changes in the proportion of T or NK cells 24 h later. Both types of radiation induced the transcription and the secretion of IL-2, IFN-γ and TNF-α, and an increase in the cytotoxic activity of the irradiated PBMCs. These effects appeared stronger with high than with low LET radiation.

Altogether, experimental data do not indicate a linear dose response relationship of immunological parameters modulation. IR may have qualitatively different effects at different doses/dose ranges. However, some responses/endpoints display discontinuous characteristics shared with non (DNA)-targeted properties of IR. The molecular mechanisms responsible for these non-linear dose response relationships, however, remain elusive and may be associated with a connexion of multiple pathways initiated at different threshold doses and following different kinetics. There is growing evidence for a mechanistic link between transcription factor activity including p53 protein, activating protein 1 (AP-1), and NF-κB in the regulation of the DDR and that of immune response. For example, a dose-dependent biphasic transcriptional activity of NF-κB has been shown in endothelial cells (ECs) and macrophages.

Initiation of anti-inflammatory vs pro-inflammatory processes by IR

Functional changes in immune parameters after low dose exposure show a significant degree of heterogeneity and are often qualitatively different from changes induced by high doses. Inflammatory response is the best studied immune mechanism which is regulated differentially by low/medium dose and high dose irradiation. In the next paragraphs we summarize the current knowledge on the regulation of inflammatory processes by low versus high dose irradiation (Fig. 2).

Modulation of basic inflammatory mechanisms by low/medium dose radiation exposure

Inflammation is a basic immunological effector process in response to harmful stimuli, such as pathogens, damaged cells or irritants and is regulated by complex interactions between a variety of immune components and soluble mediators.

Among the initial step in the inflammatory pathways is the recruitment of leukocytes to the site of damaged tissue mediated by local adhesion to the endothelium. By analysing PBMC and polymorphonuclear (PMN: granulocytes) cell attachment to cytokine TNF-α activated endothelium a significant reduction of adhesion in the dose range of 0.3–0.7 Gy was among the first mechanisms reported to contribute to an anti-inflammatory effects of intermediate dose exposure. These findings functionally coincide with secretion of the anti-inflammatory cytokine TGF-β1 from ECs, both in vitro and in a murine model. Subsequent studies further indicate an impaired adhesion to be associated with a non-linear production of reactive oxygen species (ROS) in ECs, which is functionally based on a modulation of the transcription factor nuclear factor E2-related factor 2 (Nrf2) and anti-oxidative enzymes such as superoxide dismutase, catalase and glutathione peroxidase. Further, clearance of apoptotic cells by macrophages is reported to result in non– or even anti-inflammatory responses. In line with that, a discontinuous appearance of apoptosis was observed in PBMCs following 0.1–0.3 Gy irradiation, which may foster a reduced adhesion. This is enhanced by a diminished surface expression of the adhesion molecule E-selectin on ECs or by the proteolytic cleavage of L-selectin from apoptotic PBMCs.

A key mechanism in the subsequent effector phase of inflammation covers the accumulation of monocytes and their differentiation into DCs and inflammatory macrophages. The latter support the local inflammatory process by a variety of functions such as phagocytosis, presentation of antigens, cytotoxic activity and secretion of cytokines, ROS and nitric oxide (NO). NO in turn impacts on vascular permeability, promotes tissue oedema and is involved in the development of inflammatory pain. Notably, irradiation at 0.3–1.25 Gy of activated macrophages resulted in decreased expression of the enzyme inducible nitric oxide synthase (iNOS) and NO production in line with a hampered release of ROS and superoxide production that have mechanistically been linked to the anti-inflammatory and analgesic effects of low-dose exposure. In addition, irradiation with doses up to 2 Gy significantly decreased major histocompatibility (MHC) II expression and transmigration of macrophages but fostered chemotaxis of LPS activated macrophages without impacting viability and phagocytic functions.

In order to establish experimental conditions mimicking as close as possible the patients situation, a human TNF-α transgenic mouse model was adopted to investigate the therapeutic and cellular effects of low dose irradiation. These animals overexpress the cytokine during their lifetime and develop a polyarthritis with joint swelling and deformation, synovial inflammation, cartilage damage, and bone erosion comparable to the human situation. Irradiation of these mice with five times 0.5 Gy at early stages (4–6 weeks) revealed significantly reduced paw swelling and increased grip strength. More recent findings further indicate a significant reduction of inflammatory and erosive areas with a lowered detection of bone-resorbing osteoclasts and neutrophils. In addition, starting at a dose of 0.5 Gy, proliferation and expression of receptor activator of NF-kB ligand (RANK-L) in fibroblast-like synoviocytes decreased, numbers of differentiated osteoclasts and their bone resorbing activity also diminished in line with a discontinuous dose response relationship in osteoblast-induced mineralization. By contrast, irradiation with a single dose of 0.5 Gy displayed no harmful effects on cells in healthy joints. Thus, one can conclude that in this dose range irradiation may also act via osteo-immunological mechanism with the anti-inflammatory properties depending on the initial inflammatory status. In conclusion, recent experimental in vitro data have characterized mechanisms and factors that may contribute to the anti-inflammatory effect of a low to medium dose exposure while in vivo models have confirmed improvements in a variety of clinical symptoms and parameters.

First clinical studies of patients that had been exposed to very low doses of high linear energy transfer (LET) radon gas (0.3 mSv) gave first hints that even here systemic immune modulations took place. Especially, activation status of immune cells was influenced as well as levels of TGF-β. One of the most compelling observations in this patient population was a long-term shift within the CD4+ T cell compartment towards a higher proportion of circulating Tregs along with a fall in CD8+ T cells after cumulative doses of around 0.3 mSv. Decreased levels of lymphocytes expressing the activation marker CD69 and a temporary rise in systemic TGF-β and higher IL-18 serum levels were found to directly relate to better pain control in patients after radon spa treatment.

Lung injury during radiotherapy – A clinical example of radiation-induced pro-inflammatory pathology

The lung is one of the most radiosensitive organs, and RT-associated lung tissue inflammation can occur early (radiation pneumonitis, within 6 months) and late (chronic lung fibrosis, later than 6 months) after RT. Currently, radiation pneumonitis develops in about 30% of patients and is fatal in 2%. It is the main dose-limiting toxicity and can limit quality of life of cancer survivors. Genetic factors contribute to the severity of the radiation-induced pneumonitis and fibrosis. Pathophysiology, molecular and cellular mechanisms of these injuries have been described, however still remain not fully understood.

After irradiation, as a consequence of radiation-induced oxidative stress the DDR is dysregulated in lung, resulting in a population of cells with unrepaired DNA damage. This in turn leads to destruction of alveolar epithelial and vascular ECs inducing tissue hypoxia. Oxidative stress and tissue hypoxia are important regulators of cellular signalling pathways controlling the production of various factors involved in the development of radiation-induced lung injury such as secretion of pro-inflammatory and pro-fibrogenic cytokines, growth factors and pro-teases that destroy the extracellular matrix and the barrier of lung tissue. Hypoxia-inducible factor 1α (HIF-1α) protein is an important transcription factor involved in the development of radiation-induced lung injury, which is expressed early after irradiation as a consequence of oxidative stress and tissue hypoxia and its expression progressively increases for months thereafter. Once induced, it regulates the expression of a series of genes involved in pathways like inflammation, oxidative stress response, proliferation, differentiation or angiogenesis. Blood vessel dilation and increased permeability allows for accumulation of inflammatory cells (with macrophages being the most prominent cell types) at the site of irradiated tissue and in the alveolar cavity and cause a strong immune response. This acute inflammatory response may lead to radiation pneumonitis that induces a vicious circle of further inflammation and finally fibrosis induction. IR leads to release of cytokines as well. A first wave of cytokine release settles within two weeks. The second wave starts around 6–8 weeks post-irradiation and is associated with accumulation of oxidative DNA damage, ROS or reactive nitrogen species (RNS), hypoxia, TGF-β expression, and decreased lung perfusion. TGF-β, in particular, TGF-β1, is mainly generated by activated macrophages and is a key player in development of fibrosis. It triggers proliferation and conversion of fibroblasts to myofibroblasts. Myofibroblasts in turn produce excessive collagen and other extracellular matrix components, and secrete angiotensin and hydrogen peroxide, which induce apoptosis in alveolar epithelial cells. Activin A is induced by TGF-β1 and it also stimulates production of collagen. Fibrosis induces hypoxia and consequent release of pro-fibrotic and pro-angiogenic factors like TGF-β1. These cycles are the basis of RT-induced chronic inflammatory lung disease.

Clinical predictors have been identified in an effort to minimize radiation pneumonitis. Since the inflammatory response underlies RT-related lung toxicities, immunological factors involved in this response may provide potential biomarkers to predict individual response to RT. Lierova et al. recently reviewed 56 articles that have evaluated the association between serum cytokines and pneumonitis in irradiated lung cancer patients, most of them receiving around 60 Gy. Serum IL-6 and TGF-β1 tended to stand out in predicting susceptibility to subacute pneumonitis, whereas circulating IL-4 and IL-13 appeared more critical for delayed effects such as chronic inflammation and fibrosis. Higher grade pulmonary toxicity in lung cancer patients was associated with early changes during RT treatment in plasma levels of IP-10, MCP-1, eotaxin, IL-6, and tissue inhibitor of matrix metalloproteinase 1 (TIMP1). The expression levels of follistatin, the member of TGF-β superfamily, fibrillin-2, which stores the latent form of TGF-β in extracellular matrix and inhibits its activation, and dermatopontin, which increases cellular response to TGF-β, predicted lung radiosensitivity manifested as radiation-induced fibrosis. Vascular endothelial growth factor, E-selectin, I-selectin, basic fibroblast growth factor (bFGF), IL-1, IL-6, IL-8, IL-10, IL-12 and IL-18 have also been suggested as possible predictive biomarkers.

Chronic inflammatory responses as predictors of radiation toxicity have also been described in patients treated with RT for other malignancies than lung cancer. A recent review by Marconi et al. included 15 publications from the last 5 years on breast cancer patients receiving RT, many with conventionally fractionated regimens to a total dose of 50 Gy. Some radiation-driven changes in cytokine levels persisted in these patients for months, such as IFN-γ and TGF-β. Similarly to lung, both IL-6 and TGF-β correlated with radiation toxicity, although tumour stage and timing were important factors, too. Moreover, in 37 patients with prostate cancer receiving RT, cytokines were reported to appear in recurring waves with pro-inflammatory IL-1 and macrophage colony-stimulating factor (M-CSF) preceding TGF-β1 but more importantly the magnitude of these waves correlated with doses up to 9 Gy given in daily 1.8 Gy fractions.

Altogether, these clinical observations indicate that chronic inflammatory reactions are key players in the pathophysiology of high dose irradiation-induced normal tissue toxicity.

Although not directly linked to the topic of the paper, we would like to briefly mention that a cancer developing in an inflammatory microenvironment is in general more radioresistant compared to a cancer where chronic inflammation is not present. The link between local inflammation and cancer radioresistance is thoroughly investigated and several excellent reviews exist on this topic.

An important point to consider when comparing inflammatory responses after cancer RT with low dose radiation treatment of benign diseases is the different initial temporal and spatial states of the immune system. Many cancer patients have a more immune-suppressive tumor microenvironment, in contrast to the chronic inflammatory state in benign disease; both of which are far from the more balanced, neutral set-point in healthy people. As the baseline immune balance has shifted, the effect of radiation will shift also.

The role of genetic background in the variability of radiation effects on the immune system

Individual variation in response to IR is well documented in cancer patients receiving RT and radiosensitive patients can present therapy-related side effects such as fibrosis, necrosis, dermatitis, esophagitis, neuropathological disorders, inflammation and vascular damage, among others. The mechanism of inflammation and fibrosis developing in lung after RT has been described in the previous chapter and it is evident that many of the adverse effects involve processes of the immune system. Heritability studies suggest that 58–82% of the individual variation in sensitivity to radiation and in the development of RT-related toxicity can be attributed to genetic factors. Currently the role of the genetic background in individual radiosensitivity has almost exclusively been investigated for high doses and practically no data exist in the literature regarding low dose effects. We aim to provide a short summary of the data available regarding the role of the genetic background in the immune system changes influencing individual radiation response.

Several studies with murine models have shown genotype-dependent inflammatory-type responses after whole-body irradiation. For example, macrophages from CBA/Ca mice exhibited a pro-inflammatory phenotype, whereas those from C57BL/6 showed an anti-inflammatory phenotype after irradiation with 4 Gy. Moreover, different immune-related outputs were obtained after doses below 100 mGy in two mouse strains with different sensitivity to radiation-induced mammary carcinoma: the sensitive strain but not the resistant one showed transcriptional signatures of macrophage activation, pattern recognition receptor signalling, NK cell and TGF-β signalling. While changes in immune gene signatures were transient, activation of various cancer pathways in the sensitive strain after irradiation was a durable effect. This would confirm the importance of genetic background in low dose IR-induced effects.

It is well known that rare mutations in DNA DSB repair genes can cause heritable syndromes, such as ataxia telangiectasia, that show extreme radiosensitivity. However, radiosensitivity is now considered not to rely only on a single rare gene mutation but to be an inherited complex trait that depends on the interaction of common risk alleles in a large number of genes. The different responses to RT in patients treated with the same radiation doses and not affected by one of the above-mentioned heritable syndromes, support the consensus of the involvement of common genetic factors in radiosensitivity.

The degree of the association between specific genes and pathways and sensitivity to radiation probably depends on the specific tissue involved and the particular endpoint analysed. Focusing on the immune system, some genetic variants (mainly single nucleotide polymorphisms (SNPs)) have been found to be associated with inflammation and fibrosis after radiation and in particular after RT (Table 4). For example, in early studies with relatively small sample sizes, polymorphisms in glutathione S-transferase alpha1 (GSTA1), glutathione S-transferase pi1 (GSTP1), TGF-β1, thioredoxin reductase 2 (TXNRD2), and X-ray repair cross-complementing 1 (XRCC1) genes were found to be significantly associated with radiation-induced fibrosis in breast cancer patients. On the other hand, polymorphisms in ataxia telangiectasia mutated (ATM), ERCC excision repair 5, endonuclease (ERCC5), mouse double minute 2 (MDM2), XRCC1 and XRCC3 were associated with fibrosis in naso-pharyngeal cancer patients. This would agree with the tissue-specificity of the associations in some cases. However, some studies failed to replicate the initial associations for TGF-β1, XRCC1 and XRCC3 (see Table 4 for references).

Later, more-powered studies were carried out (and some are still ongoing) in collaborative projects with thousands of patients, e.g. RadGenomics, GENEPI, Gene-PARE, RAPPER, and REQUITE. These collaborative projects have successfully identified association of alleles from the MHC III region with fibrosis in 2036 breast cancer patients and of ribonuclease L (RNASEL) gene with IL-6 levels in 2550 prostate cancer patients. However, a large study with 2782 patients reported no association of a SNP in TGF-β1 gene with RT-induced breast fibrosis. Similarly, results from Zhu et al. with 2926 patients with several cancer types failed to find a correlation between TGF-β1 SNPs and fibrosis after RT.

All these studies were focused on candidate genes suspected to be causally related to radiation toxicity, such as DNA damage recognition and repair, free radical scavenging or anti-inflammatory response. Besides the candidate-gene approach, few genome-wide association studies (GWAS) have been carried out to unravel genes important in radiosensitivity unbiasedly. Most of these GWAS provided evidence for associations of polymorphisms with overall toxicity after RT or with individual endpoints other than inflammation or fibrosis, so candidate gene approach studies previously mentioned (Table 3) could not be confirmed or refuted. However, some GWAS identified genetic variants that may underlie the variability of radiation effects on the immune system, specifically in prostate cancer patients treated with RT and who presented rectal bleeding, which could be caused by proctitis or inflammation of the rectum. Recently, Kerns et al. performed a meta-analysis with 3871 prostate cancer patients and identified one SNP significantly associated with rectal bleeding.

In conclusion the role of genetic background in shaping the individual immune response after high doses is well demonstrated even in the absence of identified consensus on the identity of the gene(s) or gene cluster(s) responsible for this effect. While studies investigating the role of genetic background in individual immune parameters to low dose IR are very scarce in the literature there is no doubt that an individual genetic signature is crucial in low dose response as well, especially taking into account the high inter-individual variability of low dose effects, which are most probably governed by genetic (and epigenetic) factors. This highlights the future need to focused research deciphering the role of genetic background in low dose regulated immune responses.

Conclusions

There is a wealth of scientific evidence based on epidemiological data from various cohorts exposed to different radiation doses, dose rates and radiation qualities as well as clinical studies and experimental in vitro and in vivo data, all collectively supporting the notion that low dose IR affects the immune system in multiple ways.

The most important of these findings can be summarized as follows:

Both studies on human subjects and experimental data indicate low dose radiation-induced damage on T cell immunity, especially CD4+ T cells. There is a fair amount of consensus in the literature on low dose radiation doses driving changes in the functional profile of CD4+ T cells, most often a shift towards a Th2 phenotype. CD8+ damage (both quantitative and functional) is also reported in most studies but there are discrepancies as to their radiosensitivity and their functional impairment depending on whether acute or long term chronic exposures were performed. It is also known that T cell activation can drive radioresistancy, which may explain some of these discrepancies.

Data regarding low dose radiation effects on humoral immunity mostly arise from epidemiological observations and relatively few experimental studies have focused on this component of the immune system. While most studies show some degree of humoral immune enhancement, these are in contradiction with sporadic reports on an increased proneness to bacterial infections among radiation exposed individuals, although this may vary with the infectious agent.

Within the innate immune system, NK cells are perhaps the best studied lineage and there is a relative consensus both in epidemiological and experimental data on the role of low dose radiation in stimulating certain types of NK cells. Reports about low dose radiation effects on other components of the innate immune system are either contradictory (DCs) or are too few (polymorphonuclear cells) to allow for any pertinent conclusion regarding their behaviour post exposure.

There is an interesting dichotomy when it comes to inflammatory responses in the context of low dose radiation. We can surely state that low-to-moderate doses of low and high LET radiation have anti-inflammatory effects on individuals with local inflammatory conditions and may result in improvement in a variety of clinical symptoms and parameters. On the other hand long-term observations of cohorts exposed to very low doses of radiation (acute or chronic) indicate a pro-inflammatory immune profile, which might contribute to increased incidence of chronic degenerative diseases with an inflammatory component.

Epidemiological studies were the first to raise the possibility of a radiation-induced acceleration of immune aging as well as radiation-induced metabolic perturbations in immune cells. Recently experimental data seem to validate these observations, though low dose studies in these topics are extremely few.

Recommendations for future research

Despite all the data presented here, there are still some research gaps that need to be filled and we present some recommendations for future studies:

Dysregulation of the immune system is thought to play a key role in many adverse health outcomes following exposure to IR. These can be cancerous or non-cancerous, such as cardiovascular, neuro-cognitive and metabolic diseases, as described by Tapio et al. in another paper of this special issue. Clearly one of the greatest gaps in epidemiological studies is that immune changes identified in different cohorts are not linked to changes in the incidence of particular diseases. These are intricately linked and need to be studied together, i.e. the role of the immune system in radiation-induced chronic non-cancer diseases such as cardiovascular, neuro-cognitive, metabolic diseases or autoimmune disorders. A better understanding of the mechanisms would allow us to develop effective countermeasures and to identify predictive biomarkers. Given the nature of the immune system, immune parameters considered to be in the normal range show very high variability in the population at large but are relatively constant at an individual level. Hence, looking at population means might easily mask individual changes. Ideally, in order to correctly evaluate individual changes they should be compared to pre-exposure values of the particular individual if possible, in addition to mean values of control population. Since most immune monitoring is performed on blood samples, future epidemiological studies should aim to include data from pre-exposure blood samples as well as include potential covariates/confounders such as additional stressors, lifestyle factors and genetic background.

Most evidence indicates that the relationship between IR exposure and immunological changes is anything but linear. In some instances, low, intermediate and high IR doses of different radiation qualities and applied in different dose rates induce discontinuous or biphasic effects on the immune system. However experimental data also show that low/intermediate versus high doses (or dose ranges) induce qualitatively different shifts in immune responses (e. g. the shift from Th1 to Th2 profile of T helper cells or a shift from a pro-inflammatory towards an anti-inflammatory response or vice versa). The effects of low/intermediate doses may depend on the initial inflammatory state of the irradiated tissue, the dose rate and quality of radiation. Big gaps exist in our knowledge of the molecular events responsible for these different response patterns. A better understanding of these mechanisms would enable a better control of radiation-induced immune changes. In line with that, one major characteristics of the immune system is a high degree of cellular motility and interaction dynamics of the different components to activate host-protective activities and to terminate immune responses to counteract chronic and harmful activation. Thus, multiple sampling and the usage of multiplexed, high-resolution in situ examination is recommended to unravel the complexity of immune interactions.

Syngenic animal studies and image guided irradiation of distinct locations in animals can greatly help in understanding radiation-induced immune changes. However, emphasis should be placed on long-term follow-up studies to identify persistent rather than transient immune changes. Currently available animal experiments are mostly investigating acute or short-term changes which are not really relevant for identifying late occurring pathological immune-related alterations.

It might be useful to take into account the state of the art in other fields in the study of the effects of IR on the immune system. Firstly, the immune system has a vast but limited number of mechanisms to respond to stressors. Commonalities of the mechanisms induced by stressors not related to IR can be expected and useful to elucidate radiation-related mechanisms. Secondly, immune responses in other organisms (including invertebrates and plants) may be one of the synergetic fields of research between radiobiologists and radioecologists. Third, as combined stressors reflect better the reality than exposure to IR alone, an exposome research approach considering the effects of environmental pollutants, nutrition, lifestyle factors as suggested above might be needed to reveal a more realistic effect of IR.

Concerning the medical applications of low dose IR, there is a need to further explore the immunomodulatory effect of both low and high LET radiation. For example for radon, the development of suitable in vivo platforms and basic models in line with extended translational and clinical research is seriously needed.

References 256

  1. 1.

    Abuodeh Y, Venkat P, Kim S, 2016. Systematic review of case reports on the abscopal effect. Curr. Probl. Cancer 40, 25–37..

    Not in our library10.1016/j.currproblcancer.2015.10.001

  2. 2.

    Agate L, Mariotti S, Elisei R, Mossa P, Pacini F, Molinaro E, Grasso L, Masserini L, Mokhort T, Vorontsova T, Arynchyn A, Tronko MD, Tsyb A, Feldt-Rasmussen U, Juul A, Pinchera A, 2008. Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. J. Clin. Endocrinol. Metab. 93, 2729–2736..

    Not in our library10.1210/jc.2008-0060

  3. 3.

    Aggarwal BB, Vijayalekshmi RV, Sung B, 2009. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 15, 425–430..

    Not in our library10.1158/1078-0432.ccr-08-0149

  4. 4.

    Ahmad IM, Temme JB, Abdalla MY, Zimmerman MC, 2016. Redox status in workers occupationally exposed to long-term low levels of ionizing radiation: A pilot study. Redox Rep. 21, 139–145..

    Not in our library10.1080/13510002.2015.1101891

  5. 5.

    Akiyama M, 1995. Late effects of radiation on the human immune system: an overview of immune response among the atomic-bomb survivors. Int. J. Radiat Biol. 68, 497–508..

    Not in our library10.1080/09553009514551491

  6. 6.

    Akiyama M, Yamakido M, Kobuke K, Dock DS, Hamilton HB, Awa AA, Kato H, 1983. Peripheral lymphocyte response to PHA and T cell population among atomic bomb survivors. Radiat. Res. 93, 572–580.

    Not in our library

  7. 7.

    Akleyev AA, Blinova EA, Dolgushin II, 2019. Immunological status of chronically exposed persons with increased level of TCR mutations. Radiat. Environ. Biophys. 58, 81–88..

    Not in our library10.1007/s00411-018-0766-1

  8. 8.

    Alsbeih G, El-Sebaie M, Al-Rajhi N, Al-Harbi N, Al-Hadyan K, Al-Qahtani S, Alsubael M, Al-Shabanah M, Moftah B, 2014. Among 45 variants in 11 genes, HDM2 promoter polymorphisms emerge as new candidate biomarker associated with radiation toxicity. 3 Biotech 4 137–148..

    Not in our library10.1007/s13205-013-0135-3

  9. 9.
    Pattern Recognition Receptors and the Host Cell Death Molecular Machinery · 2018
    No notice
  10. 10.

    Anderson RE, Warner NL, 1976. Ionizing radiation and the immune response. Adv. Immunol. 24, 215–335..

    Not in our library10.1016/s0065-2776(08)60331-4

  11. 11.

    Andreassen CN, Alsner J, Overgaard J, 2002. Does variability in normal tissue reactions after radiotherapy have a genetic basis–where and how to look for it? Radiother. Oncol. 64, 131–140..

    Not in our library10.1016/s0167-8140(02)00154-8

  12. 12.

    Arenas M, Gil F, Gironella M, Hernandez V, Jorcano S, Biete A, Pique JM, Panes J, 2006. Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice. Int. J. Radiat. Oncol. Biol. Phys. 66, 560–567..

    Not in our library10.1016/j.ijrobp.2006.06.004

  13. 13.

    Artis D, Spits H, 2015. The biology of innate lymphoid cells. Nature 517, 293–301..

    Not in our library10.1038/nature14189

  14. 14.

    Attar M, Molaie Kondolousy Y, Khansari N, 2007. Effect of high dose natural ionizing radiation on the immune system of the exposed residents of Ramsar Town Iran. Iran J Allergy Asthma Immunol 6, 73–78 doi: 06.02/ijaai.7378.

    Not in our library

  15. 15.

    Balazs K, Kis E, Badie C, Bogdandi EN, Candeias S, Garcia LC, Dominczyk I, Frey B, Gaipl U, Juranyi Z, Kocsis ZS, Rutten EA, Safrany G, Widlak P, Lumniczky K, 2019. Radiotherapy-induced changes in the systemic immune and inflammation parameters of head and neck cancer patients. Cancers (Basel) 11..

    Not in our library10.3390/cancers11091324

  16. 16.

    Balogh A, Persa E, Bogdandi EN, Benedek A, Hegyesi H, Safrany G, Lumniczky K, 2013. The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells. Inflamm. Res. 62, 201–212..

    Not in our library10.1007/s00011-012-0567-y

  17. 17.

    Barnett GC, Coles CE, Burnet NG, Pharoah PD, Wilkinson J, West CM, Elliott RM, Baynes C, Dunning AM, 2010. No association between SNPs regulating TGF-beta1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother. Oncol. 97, 9–14..

    Not in our library10.1016/j.radonc.2009.12.006

  18. 18.

    Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, Chang-Claude J, Coles CE, Gutierrez-Enriquez S, Fuentes-Raspall MJ, Alonso-Munoz MC, Kerns S, Raabe A, Symonds RP, Seibold P, Talbot CJ, Wenz F, Wilkinson J, Yarnold J, Dunning AM, Rosenstein BS, West CM, Bentzen SM, 2012. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother. Oncol. 105, 289–295..

    Not in our library10.1016/j.radonc.2012.10.017

  19. 19.

    Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, Dorling L, Coles CE, Dearnaley DP, Rosenstein BS, Vega A, Symonds P, Yarnold J, Baynes C, Michailidou K, Dennis J, Tyrer JP, Wilkinson JS, Gomez-Caamano A, Tanteles GA, Platte R, Mayes R, Conroy D, Maranian M, Luccarini C, Gulliford SL, Sydes MR, Hall E, Haviland J, Misra V, Titley J, Bentzen SM, Pharoah PD, Burnet NG, Dunning AM, West CM, 2014. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother. Oncol. 111, 178–185..

    Not in our library10.1016/j.radonc.2014.02.012

  20. 20.

    Baumann M, Holscher T, Begg AC, 2003. Towards genetic prediction of radiation responses: ESTRO’s GENEPI project. Radiother. Oncol. 69, 121–125..

    Not in our library10.1016/j.radonc.2003.08.006

  21. 21.

    Beels L, Werbrouck J, Thierens H, 2010. Dose response and repair kinetics of gamma-H2AX foci induced by in vitro irradiation of whole blood and T-lymphocytes with X- and gamma-radiation. Int. J. Radiat Biol. 86, 760–768..

    Not in our library10.3109/09553002.2010.484479

  22. 22.

    Bogdandi EN, Balogh A, Felgyinszki N, Szatmari T, Persa E, Hildebrandt G, Safrany G, Lumniczky K, 2010. Effects of low-dose radiation on the immune system of mice after total-body irradiation. Radiat. Res. 174, 480–489..

    Not in our library10.1667/rr2160.1

  23. 23.

    Borchiellini D, Etienne-Grimaldi MC, Bensadoun RJ, Benezery K, Dassonville O, Poissonnet G, Llorca L, Ebran N, Formento P, Chateau Y, Thariat J, Milano G, 2017. Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer. Oral Oncol. 67, 70–76..

    Not in our library10.1016/j.oraloncology.2017.02.003

  24. 24.

    Borzoueisileh S, Monfared AS, Abediankenari S, Mostafazadeh A, 2013. The assessment of cytotoxic T cell and natural killer cells activity in residents of high and ordinary background radiation areas of Ramsar-Iran. J Med Phys 38, 30–33..

    Not in our library10.4103/0971-6203.106602

  25. 25.

    Burnet NG, Barnett GC, Elliott RM, Dearnaley DP, Pharoah PD, Dunning AM, West and Rapper Investigators, C.M. 2013. RAPPER: the radiogenomics of radiation toxicity. Clin Oncol (R Coll Radiol) 25: 431–434. doi:.

    Not in our library10.1016/j.clon.2013.04.001

  26. 26.

    Candeias SM, Mika J, Finnon P, Verbiest T, Finnon R, Brown N, Bouffler S, Polanska J, Badie C, 2017. Low-dose radiation accelerates aging of the T-cell receptor repertoire in CBA/Ca mice. Cell. Mol. Life Sci. 74, 4339–4351..

    Not in our library10.1007/s00018-017-2581-2

  27. 27.

    Candeias SM, Testard I, 2015. The many interactions between the innate immune system and the response to radiation. Cancer Lett. 368, 173–178..

    Not in our library10.1016/j.canlet.2015.02.007

  28. 28.

    Chang WP, Hwang JS, Hung MC, Hu TH, Lee SD, Hwang BF, 1999a. Chronic low-dose gamma-radiation exposure and the alteration of the distribution of lymphocyte subpopulations in residents of radioactive buildings. Int. J. Radiat Biol. 75, 1231–1239..

    Not in our library10.1080/095530099139386

  29. 29.

    Chang WP, Lin YP, Hwang PT, Tang JL, Chen JY, Lee SD, 1999b. Persistent leucocyte abnormalities in children years after previous long-term low-dose radiation exposure. Br. J. Haematol. 106, 954–959..

    Not in our library10.1046/j.1365-2141.1999.01633.x

  30. 30.

    Chen H, Wu M, Li G, Hua L, Chen S, Huang H, 2017. Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: A cohort study. Medicine (Baltimore) 96..

    Not in our library10.1097/md.0000000000008202

  31. 31.

    Chen Y, Li Y, Zhang H, Xie Y, Chen X, Ren J, Zhang X, Zhu Z, Liu H, Zhang Y, 2010. Early effects of low dos C ion or X-ray irradiation on human peripheral blood lymphocytes. Adv. Space Res. 45, 832–838..

    Not in our library10.1016/j.asr.2009.09.024

  32. 32.

    Chen Y, Zhu M, Zhang Z, Jiang G, Fu X, Fan M, Sun M, Wei Q, Zhao K, 2013. A NEIL1 single nucleotide polymorphism (rs4462560) predicts the risk of radiation-induced toxicities in esophageal cancer patients treated with definitive radiotherapy. Cancer 119, 4205–4211..

    Not in our library10.1002/cncr.28338

  33. 33.

    Chernyshov VP, Vykhovanets EV, Slukvin II, Antipkin YG, Vasyuk AN, Strauss KW, 1997. Analysis of blood lymphocyte subsets in children living on territory that received high amounts of fallout from Chernobyl accident. Clin. Immunol. Immunopathol. 84, 122–128..

    Not in our library10.1006/clin.1997.4369

  34. 34.

    Cheuk IW, Yip SP, Kwong DL, Wu VW, 2014. Association of XRCC1 and XRCC3 gene haplotypes with the development of radiation-induced fibrosis in patients with nasopharyngeal carcinoma. Mol. Clin. Oncol. 2, 553–558..

    Not in our library10.3892/mco.2014.276

  35. 35.

    Cho SJ, Kang H, Hong EH, Kim JY, Nam SY, 2018. Transcriptome analysis of low-dose ionizing radiation-impacted genes in CD4(+) T-cells undergoing activation and regulation of their expression of select cytokines. J. Immunotoxicol. 15, 137–146..

    Not in our library10.1080/1547691x.2018.1521484

  36. 36.

    Coates PJ, Rundle JK, Lorimore SA, Wright EG, 2008. Indirect macrophage responses to ionizing radiation: implications for genotype-dependent bystander signaling. Cancer Res. 68, 450–456..

    Not in our library10.1158/0008-5472.can-07-3050

  37. 37.

    Commins SP, Borish L, Steinke JW, 2010. Immunologic messenger molecules: cytokines, interferons, and chemokines. J. Allergy Clin. Immunol. 125, S53–S72..

    Not in our library10.1016/j.jaci.2009.07.008

  38. 38.

    Courtade M, Caratero A, Jozan S, Pipy B, Caratero C, 2001. Influence of continuous, very low-dose gamma-irradiation on the mouse immune system. Int. J. Radiat Biol. 77, 587–592..

    Not in our library10.1080/09553000110034621

  39. 39.
    Decrease of Markers Related to Bone Erosion in Serum of Patients with Musculoskeletal Disorders after Serial Low-Dose Radon Spa Therapy · 2017
    Not checked
  40. 40.

    Cui J, Yang G, Pan Z, Zhao Y, Liang X, Li W, Cai L, 2017. Hormetic response to low-dose radiation: focus on the immune system and its clinical implications. Int. J. Mol. Sci. 18.

    Not in our library10.3390/ijms18020280

  41. 41.
    Low-Dose Radiotherapy Ameliorates Advanced Arthritis in hTNF-α tg Mice by Particularly Positively Impacting on Bone Metabolism · 2018
    Not checked
  42. 42.

    Deloch L, Ruckert M, Fietkau R, Frey B, Gaipl US, 2018b. Low-Dose Radiotherapy Has No Harmful Effects on Key Cells of Healthy Non-Inflamed Joints. Int. J. Mol. Sci. 19.

    Not in our library10.3390/ijms19103197

  43. 43.

    Demaria S, Golden EB, Formenti SC, 2015. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1, 1325–1332..

    Not in our library10.1001/jamaoncol.2015.2756

  44. 44.

    Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC, 2004. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862–870..

    Not in our library10.1016/j.ijrobp.2003.09.012

  45. 45.

    Denkinger MD, Leins H, Schirmbeck R, Florian MC, Geiger H, 2015. HSC Aging and Senescent Immune Remodeling. Trends Immunol. 36, 815–824..

    Not in our library10.1016/j.it.2015.10.008

  46. 46.

    Denoyer D, Lobachevsky P, Jackson P, Thompson M, Martin OA, Hicks RJ, 2015. Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. J. Nucl. Med. 56, 505–511..

    Not in our library10.2967/jnumed.114.145581

  47. 47.

    Du L, Yu W, Dai X, Zhao N, Huang X, Tong F, Liu F, Huang Y, Ju Z, Yang W, Cong X, Xie C, Liu X, Liang L, Han Y, Qu B, 2018a. Association of DNA repair gene polymorphisms with the risk of radiation pneumonitis in lung cancer patients. Oncotarget 9, 958–968..

    Not in our library10.18632/oncotarget.22982

  48. 48.

    Du L, Yu W, Huang X, Zhao N, Liu F, Tong F, Zhang S, Niu B, Liu X, Xu S, Huang Y, Dai X, Xie C, Chen G, Cong X, Qu B, 2018b. GSTP1 Ile105Val polymorphism might be associated with the risk of radiation pneumonitis among lung cancer patients in Chinese population: A prospective study. J Cancer 9, 726–735..

    Not in our library10.7150/jca.20643

  49. 49.

    Edvardsen H, Landmark-Hoyvik H, Reinertsen KV, Zhao X, Grenaker-Alnaes GI, Nebdal D, Syvanen AC, Rodningen O, Alsner J, Overgaard J, Borresen-Dale AL, Fossa SD, Kristensen VN, 2013. SNP in TXNRD2 associated with radiation-induced fibrosis: a study of genetic variation in reactive oxygen species metabolism and signaling. Int. J. Radiat. Oncol. Biol. Phys. 86, 791–799..

    Not in our library10.1016/j.ijrobp.2013.02.025

  50. 50.

    Edvardsen H, Tefre T, Jansen L, Vu P, Haffty BG, Fossa SD, Kristensen VN, Borresen-Dale AL, 2007. Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence. Radiat Oncol 2, 25..

    Not in our library10.1186/1748-717x-2-25

  51. 51.

    Eheman CR, Garbe P, Tuttle RM, 2003. Autoimmune thyroid disease associated with environmental thyroidal irradiation. Thyroid 13, 453–464..

    Not in our library10.1089/105072503322021115

  52. 52.

    El-Saghire H, Michaux A, Thierens H, Baatout S, 2013a. Low doses of ionizing radiation induce immune-stimulatory responses in isolated human primary monocytes. Int. J. Mol. Med. 32, 1407–1414..

    Not in our library10.3892/ijmm.2013.1514

  53. 53.

    El-Saghire H, Thierens H, Monsieurs P, Michaux A, Vandevoorde C, Baatout S, 2013b. Gene set enrichment analysis highlights different gene expression profiles in whole blood samples X-irradiated with low and high doses. Int. J. Radiat Biol. 89, 628–638..

    Not in our library10.3109/09553002.2013.782448

  54. 54.

    El-Saghire H, Vandevoorde C, Ost P, Monsieurs P, Michaux A, De Meerleer G, Baatout S, Thierens H, 2014. Intensity modulated radiotherapy induces pro-inflammatory and pro-survival responses in prostate cancer patients. Int. J. Oncol. 44, 1073–1083..

    Not in our library10.3892/ijo.2014.2260

  55. 55.

    Ermolaeva MA, Schumacher B, 2014. Systemic DNA damage responses: organismal adaptations to genome instability. Trends Genet. 30, 95–102..

    Not in our library10.1016/j.tig.2013.12.001

  56. 56.

    Ermolaeva M, Schumacher B, 2013. The innate immune system as mediator of systemic DNA damage responses. Commun. Integr. Biol. 6.

    Not in our library10.4161/cib.26926

  57. 57.

    Esposito A, Criscitiello C, Curigliano G, 2015. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. Curr. Opin. Oncol. 27, 445–451..

    Not in our library10.1097/cco.0000000000000225

  58. 58.

    Fachal L, Gomez-Caamano A, Barnett GC, Peleteiro P, Carballo AM, Calvo-Crespo P, Kerns SL, Sanchez-Garcia M, Lobato-Busto R, Dorling L, Elliott RM, Dearnaley DP, Sydes MR, Hall E, Burnet NG, Carracedo A, Rosenstein BS, West CM, Dunning AM, Vega A, 2014. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat. Genet. 46, 891–894..

    Not in our library10.1038/ng.3020

  59. 59.

    Falcke SE, Ruhle PF, Deloch L, Fietkau R, Frey B, Gaipl US, 2018. Clinically relevant radiation exposure differentially impacts forms of cell death in human cells of the innate and adaptive immune system. Int. J. Mol. Sci. 19.

    Not in our library10.3390/ijms19113574

  60. 60.

    Forrester HB, de Kretser DM, Leong T, Hagekyriakou J, Sprung CN, 2017. Follistatin attenuates radiation-induced fibrosis in a murine model. PLoS One 12..

    Not in our library10.1371/journal.pone.0173788

  61. 61.

    Forrester HB, Li J, Leong T, McKay MJ, Sprung CN, 2014. Identification of a radiation sensitivity gene expression profile in primary fibroblasts derived from patients who developed radiotherapy-induced fibrosis. Radiother. Oncol. 111, 186–193..

    Not in our library10.1016/j.radonc.2014.03.007

  62. 62.

    Franceschi C, Ostan R, Mariotti S, Monti D, Vitale G, 2019. The aging thyroid: A reappraisal within the geroscience integrated perspective. Endocr. Rev. 40, 1250–1270..

    Not in our library10.1210/er.2018-00170

  63. 63.

    Frey B, Gaipl US, Sarter K, Zaiss MM, Stillkrieg W, Rodel F, Schett G, Herrmann M, Fietkau R, Keilholz L, 2009. Whole body low dose irradiation improves the course of beginning polyarthritis in human TNF-transgenic mice. Autoimmunity 42, 346–348..

    Not in our library10.1080/08916930902831738

  64. 64.

    Frey B, Mika J, Jelonek K, Cruz-Garcia L, Roelants C, Testard I, Cherradi N, Lumniczky K, Polozov S, Napieralska A, Widlak P, Gaipl US, Badie C, Polanska J, Candeias SM, 2020. Systemic modulation of stress and immune parameters in patients treated for prostate adenocarcinoma by intensity-modulated radiation therapy or stereotactic ablative body radiotherapy. Strahlenther. Onkol..

    Not in our library10.1007/s00066-020-01637-5

  65. 65.

    Frey B, Ruckert M, Deloch L, Ruhle PF, Derer A, Fietkau R, Gaipl US, 2017. Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases. Immunol. Rev. 280, 231–248..

    Not in our library10.1111/imr.12572

  66. 66.

    Fujiwara N, Kobayashi K, 2005. Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy 4, 281–286..

    Not in our library10.2174/1568010054022024

  67. 67.

    Fulop T, Witkowski JM, Olivieri F, Larbi A, 2018. The integration of inflammaging in age-related diseases. Semin. Immunol. 40, 17–35..

    Not in our library10.1016/j.smim.2018.09.003

  68. 68.

    Gaipl US, Voll RE, Sheriff A, Franz S, Kalden JR, Herrmann M, 2005. Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun. Rev. 4, 189–194..

    Not in our library10.1016/j.autrev.2004.10.007

  69. 69.

    Gatti RA, 2001. The inherited basis of human radiosensitivity. Acta Oncol. 40, 702–711..

    Not in our library10.1080/02841860152619115

  70. 70.

    Germain RN, Robey EA, Cahalan MD, 2012. A decade of imaging cellular motility and interaction dynamics in the immune system. Science 336, 1676–1681..

    Not in our library10.1126/science.1221063

  71. 71.

    Ghiassi-nejad M, Mortazavi SM, Cameron JR, Niroomand-rad A, Karam PA, 2002. Very high background radiation areas of Ramsar, Iran: preliminary biological studies. Health Phys. 82, 87–93..

    Not in our library10.1097/00004032-200201000-00011

  72. 72.

    Ghiassi-Nejad M, Zakeri F, Assaei RG, Kariminia A, 2004. Long-term immune and cytogenetic effects of high level natural radiation on Ramsar inhabitants in Iran. J. Environ. Radioact. 74, 107–116..

    Not in our library10.1016/j.jenvrad.2003.12.001

  73. 73.

    Giotopoulos G, Symonds RP, Foweraker K, Griffin M, Peat I, Osman A, Plumb M, 2007. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br. J. Cancer 96, 1001–1007..

    Not in our library10.1038/sj.bjc.6603637

  74. 74.

    Giridhar P, Mallick S, Rath GK, Julka PK, 2015. Radiation induced lung injury: prediction, assessment and management. Asian Pac. J. Cancer Prev. 16, 2613–2617..

    Not in our library10.7314/apjcp.2015.16.7.2613

  75. 75.

    Godekmerdan A, Ozden M, Ayar A, Gursu MF, Ozan AT, Serhatlioglu S, 2004. Diminished cellular and humoral immunity in workers occupationally exposed to low levels of ionizing radiation. Arch. Med. Res. 35, 324–328..

    Not in our library10.1016/j.arcmed.2004.04.005

  76. 76.

    Gridley DS, Rizvi A, Luo-Owen X, Makinde AY, Pecaut MJ, 2009. Low dose, low dose rate photon radiation modifies leukocyte distribution and gene expression in CD4(+) T cells. J Radiat Res 50, 139–150..

    Not in our library10.1269/jrr.08095

  77. 77.

    Grossberg AJ, Lei X, Xu T, Shaitelman SF, Hoffman KE, Bloom ES, Stauder MC, Tereffe W, Schlembach PJ, Woodward WA, Buchholz TA, Smith BD, 2018. Association of transforming growth factor beta polymorphism C-509T With radiation-induced fibrosis among patients with early-stage breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol 4, 1751–1757..

    Not in our library10.1001/jamaoncol.2018.2583

  78. 78.

    Grudzenski S, Raths A, Conrad S, Rube CE, Lobrich M, 2010. Inducible response required for repair of low-dose radiation damage in human fibroblasts. Proc. Natl. Acad. Sci. U S A 107, 14205–14210..

    Not in our library10.1073/pnas.1002213107

  79. 79.

    Guerra JL, Gomez D, Wei Q, Liu Z, Wang LE, Yuan X, Zhuang Y, Komaki R, Liao Z, 2012. Association between single nucleotide polymorphisms of the transforming growth factor beta1 gene and the risk of severe radiation esophagitis in patients with lung cancer. Radiother. Oncol. 105, 299–304..

    Not in our library10.1016/j.radonc.2012.08.014

  80. 80.

    Guo Z, Shu Y, Zhou H, Zhang W, Wang H, 2015. Radiogenomics helps to achieve personalized therapy by evaluating patient responses to radiation treatment. Carcinogenesis 36, 307–317..

    Not in our library10.1093/carcin/bgv007

  81. 81.

    Gyuleva I, Djounova J, Rupova I, 2018. Impact of low-dose occupational exposure to ionizing radiation on T-cell populations and subpopulations and humoral factors included in the immune response, 1559325818785564 Dose Response 16..

    Not in our library10.1177/1559325818785564

  82. 82.

    Gyuleva IM, Penkova KI, Rupova IT, Panova DY, Djounova JN, 2015a. Assessment of some immune parameters in occupationally exposed nuclear power plant workers: flow cytometry measurements of T lymphocyte subpopulations and immunoglobulin determination, 1559325815611901 Dose Response 13..

    Not in our library10.1177/1559325815611901

  83. 83.

    Gyuleva I, Panova D, Djounova J, Rupova I, Penkova K, 2015b. Assessment of some immune parameters in occupationally exposed nuclear power plants workers: flowcytometry measurements of T, B NK and NKT cells. Dose Response 13..

    Not in our library10.2203/dose-response.14-041.gyuleva

  84. 84.

    Habraken Y, Piette J, 2006. NF-kappaB activation by double-strand breaks. Biochem. Pharmacol. 72, 1132–1141..

    Not in our library10.1016/j.bcp.2006.07.015

  85. 85.

    Hader M, Frey B, Fietkau R, Hecht M, Gaipl US, 2020. Immune biological rationales for the design of combined radio- and immunotherapies. Cancer Immunol. Immunother. 69, 293–306..

    Not in our library10.1007/s00262-019-02460-3

  86. 86.

    Hardy RR, Hayakawa K, 2001. B cell development pathways. Annu. Rev. Immunol. 19, 595–621..

    Not in our library10.1146/annurev.immunol.19.1.595

  87. 87.

    Hayashi T, Lynch HE, Geyer S, Yoshida K, Furudoi K, Sasaki K, Morishita Y, Nagamura H, Maki M, Hu Y, Hayashi I, Kyoizumi S, Kusunoki Y, Ohishi W, Fujiwara S, Misumi M, Shterev I, Nikolich-Zugich J, Murasko D, Hale LP, Sempowski GD, Nakachi K, 2018. Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort. Vaccine 36, 6650–6659..

    Not in our library10.1016/j.vaccine.2018.09.054

  88. 88.
    Danger signals – damaged-self recognition across the tree of life · 2014
    No notice
  89. 89.

    Hellweg CE, 2015. The Nuclear Factor kappaB pathway: A link to the immune system in the radiation response. Cancer Lett. 368, 275–289..

    Not in our library10.1016/j.canlet.2015.02.019

  90. 90.

    Heylmann D, Rodel F, Kindler T, Kaina B, 2014. Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells. Biochim. Biophys. Acta, Rev. Cancer 1846, 121–129..

    Not in our library10.1016/j.bbcan.2014.04.009

  91. 91.

    Hildebrandt G, Maggiorella L, Rodel F, Rodel V, Willis D, Trott KR, 2002. Mononuclear cell adhesion and cell adhesion molecule liberation after X-irradiation of activated endothelial cells in vitro. Int. J. Radiat Biol. 78, 315–325..

    Not in our library10.1080/09553000110106027

  92. 92.

    Hildebrandt G, Seed MP, Freemantle CN, Alam CA, Colville-Nash PR, Trott KR, 1998. Mechanisms of the anti-inflammatory activity of low-dose radiation therapy. Int. J. Radiat Biol. 74, 367–378..

    Not in our library10.1080/095530098141500

  93. 93.

    Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X, 2010. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5..

    Not in our library10.1371/journal.pone.0012402

  94. 94.

    Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J, Rosenstein BS, 2006. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int. J. Radiat. Oncol. Biol. Phys. 65, 646–655..

    Not in our library10.1016/j.ijrobp.2006.03.006

  95. 95.

    Holthusen H, 1997. Involvement of the NO/cyclic GMP pathway in bradykinin-evoked pain from veins in humans. Pain 69, 87–92..

    Not in our library10.1016/s0304-3959(96)03262-9

  96. 96.

    Huang Y, Zhang W, Yu F, Gao F, 2017. The cellular and molecular mechanism of radiation-induced lung injury. Med. Sci. Monit. 23, 3446–3450..

    Not in our library10.12659/msm.902353

  97. 97.

    Ilienko IM, Golyarnik NA, Lyaskivska OV, Belayev OA, Bazyka DA, 2018. Expression of biological markers induced by ionizing radiation at the late period after exposure in a wide range of doses. Probl Radiac Med Radiobiol 23, 331–350..

    Not in our library10.33145/2304-8336-2018-23-331-350

  98. 98.

    Imaizumi M, Ashizawa K, Neriishi K, Akahoshi M, Nakashima E, Usa T, Tominaga T, Hida A, Sera N, Soda M, Fujiwara S, Yamada M, Maeda R, Nagataki S, Eguchi K, 2008. Thyroid diseases in atomic bomb survivors exposed in utero. J. Clin. Endocrinol. Metab. 93, 1641–1648..

    Not in our library10.1210/jc.2008-0042

  99. 99.

    Imtiyaz HZ, Simon MC, 2010. Hypoxia-inducible factors as essential regulators of inflammation. Curr. Top. Microbiol. Immunol. 345, 105–120..

    Not in our library10.1007/82_2010_74

  100. 100.

    Ina Y, Sakai K, 2005. Activation of immunological network by chronic low-dose-rate irradiation in wild-type mouse strains: analysis of immune cell populations and surface molecules. Int. J. Radiat Biol. 81, 721–729..

    Not in our library10.1080/09553000500519808

  101. 101.

    Isomura M, Oya N, Tachiiri S, Kaneyasu Y, Nishimura Y, Akimoto T, Hareyama M, Sugita T, Mitsuhashi N, Yamashita T, Aoki M, Sai H, Hirokawa Y, Sakata K, Karasawa K, Tomida A, Tsuruo T, Miki Y, Noda T, Hiraoka M, 2008. IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin. Cancer Res. 14, 6683–6689..

    Not in our library10.1158/1078-0432.ccr-07-4389

  102. 102.

    Ito R, Hale LP, Geyer SM, Li J, Sornborger A, Kajimura J, Kusunoki Y, Yoshida K, van den Brink MRM, Kyoizumi S, Manley NR, Nakachi K, Sempowski GD, 2017. Late effects of exposure to ionizing radiation and age on human thymus morphology and function. Radiat Res 187, 589–598..

    Not in our library10.1667/rr4554.1

  103. 103.

    Iwakawa M, Imai T, Harada Y, Ban S, Michikawa Y, Saegusa K, Sagara M, Tsuji A, Noda S, Ishikawa A, 2002. RadGenomics project. Nihon Igaku Hoshasen Gakkai Zasshi 62, 484–489.

    Not in our library

  104. 104.

    Jackson IL, Zhang X, Hadley C, Rabbani ZN, Zhang Y, Marks S, Vujaskovic Z, 2012. Temporal expression of hypoxia-regulated genes is associated with early changes in redox status in irradiated lung. Free Radic Biol. Med. 53, 337–346..

    Not in our library10.1016/j.freeradbiomed.2012.04.014

  105. 105.

    Jahns J, Anderegg U, Saalbach A, Rosin B, Patties I, Glasow A, Kamprad M, Scholz M, Hildebrandt G, 2011. Influence of low dose irradiation on differentiation, maturation and T-cell activation of human dendritic cells. Mutat. Res. 709–710, 32–39..

    Not in our library10.1016/j.mrfmmm.2011.02.007

  106. 106.

    Jain V, Das B, 2017. Global transcriptome profile reveals abundance of DNA damage response and repair genes in individuals from high level natural radiation areas of Kerala coast. PLoS One 12..

    Not in our library10.1371/journal.pone.0187274

  107. 107.
    Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy · 2019
    No notice
  108. 108.

    Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS, McBride WH, Schaue D, 2011. Radiation enhances regulatory T cell representation. Int. J. Radiat. Oncol. Biol. Phys. 81, 1128–1135..

    Not in our library10.1016/j.ijrobp.2010.09.034

  109. 109.

    Karakasilioti I, Kamileri I, Chatzinikolaou G, Kosteas T, Vergadi E, Robinson AR, Tsamardinos I, Rozgaja TA, Siakouli S, Tsatsanis C, Niedernhofer LJ, Garinis GA, 2013. DNA damage triggers a chronic autoinflammatory response, leading to fat depletion in NER progeria. Cell Metab. 18, 403–415..

    Not in our library10.1016/j.cmet.2013.08.011

  110. 110.
    Increase in the Th1-Cell-Based Immune Response in Healthy Workers Exposed to Low-Dose Radiation - Immune System Status of Radiology Staff · 2017
    Not checked
  111. 111.

    Kasatkina EP, Shilin DE, Rosenbloom AL, Pykov MI, Ibragimova GV, Sokolovskaya VN, Matkovskaya AN, Volkova TN, Odoud EA, Bronshtein MI, Poverenny AM, Mursankova NM, 1997. Effects of low level radiation from the Chernobyl accident in a population with iodine deficiency. Eur. J. Pediatr. 156, 916–920..

    Not in our library10.1007/s004310050742

  112. 112.

    Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G, 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025–4031.

    Not in our library10.1002/j.1460-2075.1991.tb04978.x

  113. 113.

    Kern P, Keilholz L, Forster C, Seegenschmiedt MH, Sauer R, Herrmann M, 1999. In vitro apoptosis in peripheral blood mononuclear cells induced by low-dose radiotherapy displays a discontinuous dose-dependence. Int. J. Radiat Biol. 75, 995–1003..

    Not in our library10.1080/095530099139755

  114. 114.

    Kern PM, Keilholz L, Forster C, Hallmann R, Herrmann M, Seegenschmiedt MH, 2000. Low-dose radiotherapy selectively reduces adhesion of peripheral blood mononuclear cells to endothelium in vitro. Radiother. Oncol. 54, 273–282..

    Not in our library10.1016/s0167-8140(00)00141-9

  115. 115.

    Kerns SL, Dorling L, Fachal L, Bentzen S, Pharoah PD, Barnes DR, Gomez-Caamano A, Carballo AM, Dearnaley DP, Peleteiro P, Gulliford SL, Hall E, Michailidou K, Carracedo A, Sia M, Stock R, Stone NN, Sydes MR, Tyrer JP, Ahmed S, Parliament M, Ostrer H, Rosenstein BS, Vega A, Burnet NG, Dunning AM, Barnett GC, West CM, 2016. Meta-analysis of genome wide association studies identifies genetic markers of late toxicity following radiotherapy for prostate cancer. EBioMedicine 10, 150–163..

    Not in our library10.1016/j.ebiom.2016.07.022

  116. 116.

    Kerns SL, Fachal L, Dorling L, Barnett GC, Baran A, Peterson DR, Hollenberg M, Hao K, Narzo AD, Ahsen ME, Pandey G, Bentzen SM, Janelsins M, Elliott RM, Pharoah PDP, Burnet NG, Dearnaley DP, Gulliford SL, Hall E, Sydes MR, Aguado-Barrera ME, Gomez-Caamano A, Carballo AM, Peleteiro P, Lobato-Busto R, Stock R, Stone NN, Ostrer H, Usmani N, Singhal S, Tsuji H, Imai T, Saito S, Eeles R, DeRuyck K, Parliament M, Dunning AM, Vega A, Rosenstein BS, West CML, 2020. Radiogenomics consortium genome-wide association study meta-analysis of late toxicity after prostate cancer radiotherapy. J. Natl Cancer Inst. 112, 179–190..

    Not in our library10.1093/jnci/djz075

  117. 117.

    Kerns SL, Ostrer H, Stock R, Li W, Moore J, Pearlman A, Campbell C, Shao Y, Stone N, Kusnetz L, Rosenstein BS, 2010. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 78, 1292–1300..

    Not in our library10.1016/j.ijrobp.2010.07.036

  118. 118.

    Kerns SL, Stock RG, Stone NN, Blacksburg SR, Rath L, Vega A, Fachal L, Gomez-Caamano A, De Ruysscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk M, Hixson R, Rosenstein BS, Ostrer H, 2013a. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiother. Oncol. 107, 372–376..

    Not in our library10.1016/j.radonc.2013.05.001

  119. 119.

    Kerns SL, Stock R, Stone N, Buckstein M, Shao Y, Campbell C, Rath L, De Ruysscher D, Lammering G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein BS, 2013b. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 85, e21–e28..

    Not in our library10.1016/j.ijrobp.2012.08.003

  120. 120.

    Kerns SL, Stone NN, Stock RG, Rath L, Ostrer H, Rosenstein BS, 2013c. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer. J. Urol. 190, 102–108..

    Not in our library10.1016/j.juro.2013.01.096

  121. 121.

    Kiselev SM, Sokolnikov ME, Lyss LV, Ilyina NI, 2017. Immunological monitoring of the personnel at radiation hazardous facilities. Radiat. Prot. Dosim. 173, 124–130..

    Not in our library10.1093/rpd/ncw346

  122. 122.

    Klucinski P, Mazur B, Sedek L, Aptekorz M, Cieslik P, Hrycek AH, Martirosian G, 2014. Assessment of selected B cells populations in the workers of X-ray departments. Int. J. Occup. Med. Environ. Health 27, 467–473..

    Not in our library10.2478/s13382-014-0242-3

  123. 123.

    Kovacs CJ, Daly BM, Evans MJ, Johnke RM, Lee TK, Karlsson UL, Allison R, Eaves GS, Biggs LM, 2003. Cytokine profiles in patients receiving wide-field + prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. Cytokine 23, 151–163..

    Not in our library10.1016/s1043-4666(03)00185-6

  124. 124.

    Kullmann M, Ruhle PF, Harrer A, Donaubauer A, Becker I, Sieber R, Klein G, Fournier C, Fietkau R, Gaipl US, Frey B, 2019. Temporarily increased TGFbeta following radon spa correlates with reduced pain while serum IL-18 is a general predictive marker for pain sensitivity. Radiat. Environ. Biophys. 58, 129–135..

    Not in our library10.1007/s00411-018-0768-z

  125. 125.

    Kusunoki Y, Hayashi T, 2008. Long-lasting alterations of the immune system by ionizing radiation exposure: implications for disease development among atomic bomb survivors. Int. J. Radiat Biol. 84, 1–14..

    Not in our library10.1080/09553000701616106

  126. 126.

    Kusunoki Y, Kyoizumi S, Hirai Y, Suzuki T, Nakashima E, Kodama K, Seyama T, 1998. Flow cytometry measurements of subsets of T, B and NK cells in peripheral blood lymphocytes of atomic bomb survivors. Radiat. Res. 150, 227–236.

    Not in our library

  127. 127.

    Kusunoki Y, Yamaoka M, Kasagi F, Hayashi T, MacPhee DG, Kyoizumi S, 2003. Long-lasting changes in the T-cell receptor V beta repertoires of CD4 memory T-cell populations in the peripheral blood of radiation-exposed people. Br. J. Haematol. 122, 975–984..

    Not in our library10.1046/j.1365-2141.2003.04520.x

  128. 128.

    Kusunoki Y, Yamaoka M, Kubo Y, Hayashi T, Kasagi F, Douple EB, Nakachi K, 2010. T-cell immunosenescence and inflammatory response in atomic bomb survivors. Radiat. Res. 174, 870–876..

    Not in our library10.1667/rr1847.1

  129. 129.

    Kuzmenok O, Potapnev M, Potapova S, Smolnikova V, Rzheutsky V, Yarilin AA, Savino W, Belyakov IM, 2003. Late effects of the Chernobyl radiation accident on T cell-mediated immunity in cleanup workers. Radiat. Res. 159, 109–116..

    Not in our library10.1667/0033-7587(2003)159[0109:leotcr]2.0.co;2

  130. 130.

    Kyoizumi S, Umeki S, Akiyama M, Hirai Y, Kusunoki Y, Nakamura N, Endoh K, Konishi J, Sasaki MS, Mori T,, 1992. Frequency of mutant T lymphocytes defective in the expression of the T-cell antigen receptor gene among radiation-exposed people. Mutat. Res. 265, 173–180..

    Not in our library10.1016/0027-5107(92)90046-5

  131. 131.

    Kyoizumi S, Yamaoka M, Kubo Y, Hamasaki K, Hayashi T, Nakachi K, Kasagi F, Kusunoki Y, 2010. Memory CD4 T-cell subsets discriminated by CD43 expression level in A-bomb survivors. Int. J. Radiat Biol. 86, 56–62..

    Not in our library10.3109/09553000903272641

  132. 132.

    Land WG, 2015. How evolution tells us to induce allotolerance. Exp. Clin. Transplant. 13 (Suppl 1), 46–54.

    Not in our library

  133. 133.

    Large M, Hehlgans S, Reichert S, Gaipl US, Fournier C, Rodel C, Weiss C, Rodel F, 2015. Study of the anti-inflammatory effects of low-dose radiation: The contribution of biphasic regulation of the antioxidative system in endothelial cells. Strahlenther. Onkol. 191, 742–749..

    Not in our library10.1007/s00066-015-0848-9

  134. 134.

    Lassmann M, Hanscheid H, Gassen D, Biko J, Meineke V, Reiners C, Scherthan H, 2010. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J. Nucl. Med. 51, 1318–1325..

    Not in our library10.2967/jnumed.109.071357

  135. 135.

    Li H, Liu G, Xia L, Zhou Q, Xiong J, Xian J, Du M, Zhang L, Liao L, Su X, Li Z, Luo Q, Cheng Y, Zhang T, Wang D, Yang ZZ, 2014. A polymorphism in the DNA repair domain of APEX1 is associated with the radiation-induced pneumonitis risk among lung cancer patients after radiotherapy. Br. J. Radiol. 87, 20140093..

    Not in our library10.1259/bjr.20140093

  136. 136.

    Li K, Li W, Jia Y, Liu J, Tan G, Zou J, Li X, Su Y, Lei S, Sun Q, 2019. Long-term immune effects of high-level natural radiation on Yangjiang inhabitants in China. Int. J. Radiat Biol. 95, 764–770..

    Not in our library10.1080/09553002.2019.1572250

  137. 137.

    Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z, 2016. Single nucleotide polymorphisms in CBLB, a Regulator of T-Cell response, predict radiation pneumonitis and outcomes after definitive radiotherapy for non-small-cell lung cancer. Clin Lung Cancer 17..

    Not in our library10.1016/j.cllc.2015.11.008

  138. 138.

    Lierova A, Jelicova M, Nemcova M, Proksova M, Pejchal J, Zarybnicka L, Sinkorova Z, 2018. Cytokines and radiation-induced pulmonary injuries. J. Radiat. Res. 59, 709–753..

    Not in our library10.1093/jrr/rry067

  139. 139.

    Lobrich M, Rief N, Kuhne M, Heckmann M, Fleckenstein J, Rube C, Uder M, 2005. In vivo formation and repair of DNA double-strand breaks after computed tomography examinations. Proc. Natl. Acad. Sci. U S A 102, 8984–8989..

    Not in our library10.1073/pnas.0501895102

  140. 140.

    Lopez Guerra JL, Wei Q, Yuan X, Gomez D, Liu Z, Zhuang Y, Yin M, Li M, Wang LE, Cox JD, Liao Z, 2011. Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio(chemo)therapy. Radiother. Oncol. 101, 271–277..

    Not in our library10.1016/j.radonc.2011.08.039

  141. 141.

    Lumniczky K, Safrany G, 2015. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett. 356, 114–125..

    Not in our library10.1016/j.canlet.2013.08.024

  142. 142.

    Lustig A, Shterev I, Geyer S, Shi A, Hu Y, Morishita Y, Nagamura H, Sasaki K, Maki M, Hayashi I, Furukawa K, Yoshida K, Kajimura J, Kyoizumi S, Kusunoki Y, Ohishi W, Nakachi K, Weng NP, Hayashi T, 2016. Long term effects of radiation exposure on telomere lengths of leukocytes and its associated biomarkers among atomic-bomb survivors. Oncotarget 7, 38988–38998..

    Not in our library10.18632/oncotarget.8801

  143. 143.

    Ma WL, Liu R, Huang LH, Zou C, Huang J, Wang J, Chen SJ, Meng XG, Yang JK, Li H, Yang GP, Guo CX, 2017. Impact of polymorphisms in angiogenesis-related genes on clinical outcomes of radiotherapy in patients with nasopharyngeal carcinoma. Clin. Exp. Pharmacol. Physiol. 44, 539–548..

    Not in our library10.1111/1440-1681.12738

  144. 144.

    Magne N, Toillon RA, Bottero V, Didelot C, Houtte PV, Gerard JP, Peyron JF, 2006. NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett. 231, 158–168..

    Not in our library10.1016/j.canlet.2005.01.022

  145. 145.

    Mak RH, Alexander BM, Asomaning K, Heist RS, Liu CY, Su L, Zhai R, Ancukiewicz M, Napolitano B, Niemierko A, Willers H, Choi NC, Christiani DC, 2012. A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy. Cancer 118, 3654–3665..

    Not in our library10.1002/cncr.26667

  146. 146.

    Makinodan T, James SJ, 1990. T cell potentiation by low dose ionizing radiation: possible mechanisms. Health Phys. 59, 29–34..

    Not in our library10.1097/00004032-199007000-00003

  147. 147.

    Manning G, Taylor K, Finnon P, Lemon JA, Boreham DR, Badie C, 2014. Quantifying murine bone marrow and blood radiation dose response following (18) F-FDG PET with DNA damage biomarkers. Mutat. Res. 770, 29–36..

    Not in our library10.1016/j.mrfmmm.2014.09.002

  148. 148.

    Manning G, Tichy A, Sirak I, Badie C, 2017. Radiotherapy-associated long-term modification of expression of the inflammatory biomarker genes ARG1, BCL2L1, and MYC. Front. Immunol. 8, 412..

    Not in our library10.3389/fimmu.2017.00412

  149. 149.

    Marconi R, Serafini A, Giovanetti A, Bartoleschi C, Pardini MC, Bossi G, Strigari L, 2019. Cytokine modulation in breast cancer patients undergoing radiotherapy: A revision of the most recent studies. Int. J. Mol. Sci. 20.

    Not in our library10.3390/ijms20020382

  150. 150.

    Mathias D, Mitchel RE, Barclay M, Wyatt H, Bugden M, Priest ND, Whitman SC, Scholz M, Hildebrandt G, Kamprad M, Glasow A, 2015. Low-dose irradiation affects expression of inflammatory markers in the heart of ApoE −/− mice. PLoS One 10..

    Not in our library10.1371/journal.pone.0119661

  151. 151.

    Mavragani IV, Laskaratou DA, Frey B, Candeias SM, Gaipl US, Lumniczky K, Georgakilas AG, 2016. Key mechanisms involved in ionizing radiation-induced systemic effects A current review. Toxicol. Res. (Camb) 5, 12–33..

    Not in our library10.1039/c5tx00222b

  152. 152.
    Complex DNA Damage: A Route to Radiation-Induced Genomic Instability and Carcinogenesis · 2017
    No notice
  153. 153.

    McFarland HI, Puig M, Grajkowska LT, Tsuji K, Lee JP, Mason KP, Verthelyi D, Rosenberg AS, 2012. Regulatory T cells in gamma irradiation-induced immune suppression. PLoS One 7..

    Not in our library10.1371/journal.pone.0039092

  154. 154.

    Merrick A, Errington F, Milward K, O’Donnell D, Harrington K, Bateman A, Pandha H, Vile R, Morrison E, Selby P, Melcher A, 2005. Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br. J. Cancer 92, 1450–1458..

    Not in our library10.1038/sj.bjc.6602518

  155. 155.

    Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA, 2010. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 31, 1597–1603..

    Not in our library10.1093/carcin/bgq132

  156. 156.

    Molaie Y, Latifynia A, Kalamzadeh A, Abofazeli T, Nuraie M, Khansarii N, 2012. Phagocyte functions of human subjects living in high level of natural radiation areas in Iran. J. Ayub Med. Coll Abbottabad 24, 177–179.

    Not in our library

  157. 157.

    Mothersill C, Seymour C, 2014. Implications for human and environmental health of low doses of ionising radiation. J. Environ. Radioact. 133, 5–9..

    Not in our library10.1016/j.jenvrad.2013.04.002

  158. 158.

    Mothersill C, Seymour C, 2011. Radiation-induced non-targeted effects of low doses-what, why and how? Health Phys. 100, 302..

    Not in our library10.1097/hp.0b013e3182080f0c

  159. 159.

    Multhoff G, Radons J, 2012. Radiation, inflammation, and immune responses in cancer. Front. Oncol. 2, 58..

    Not in our library10.3389/fonc.2012.00058

  160. 160.

    Murphy KM, Weaver C, 2017. Janeway’s Immunobiology. Garland Science/Taylor & Francis Group, LLC.

    Not in our library

  161. 161.

    Niu X, Li H, Chen Z, Liu Y, Kan M, Zhou D, Li Z, Ye X, Shen S, Lv C, Lu S, 2012. A study of ethnic differences in TGFbeta1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer. J. Thorac. Oncol. 7, 1668–1675..

    Not in our library10.1097/jto.0b013e318267cf5b

  162. 162.

    Oradovskaia IV, Pashchenkova Iu G, Feoktistov VV, Nikonova MF, Vikulov GKH, Bozheskaia NV, Smirnova NN, 2011a. [The epidemiological analysis of monitoring of the immune status in liquidators of consequences of the Chernobyl accident for early identification of risk groups and diagnostics of oncological diseases. Report 1]. Radiats. Biol. Radioecol. 51, 101–116.

    Not in our library

  163. 163.

    Oradovskaia IV, Pashchenkova Iu G, Feoktistov VV, Nikonova MF, Vikulov GKH, Bozheskaia NV, Smirnova NN, 2011b. [The epidemiological analysis of monitoring of the immune status in liquidators of consequences of the Chernobyl accident for early identification of risk groups and diagnostics of oncological diseases. Report 2. Dependence of frequency and changes in the immune status on risk factors of radiation accident]. Radiats Biol. Radioecol. 51, 117–133.

    Not in our library

  164. 164.

    Pacini F, Vorontsova T, Demidchik EP, Molinaro E, Agate L, Romei C, Shavrova E, Cherstvoy ED, Ivashkevitch Y, Kuchinskaya E, Schlumberger M, Ronga G, Filesi M, Pinchera A, 1997. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J. Clin. Endocrinol. Metab. 82, 3563–3569..

    Not in our library10.1210/jcem.82.11.4367

  165. 165.

    Pacini F, Vorontsova T, Molinaro E, Kuchinskaya E, Agate L, Shavrova E, Astachova L, Chiovato L, Pinchera A, 1998. Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet 352, 763–766..

    Not in our library10.1016/s0140-6736(97)11397-6

  166. 166.

    Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G, 2013. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 85, 444–450..

    Not in our library10.1016/j.ijrobp.2012.04.043

  167. 167.

    Pandey R, Shankar BS, Sharma D, Sainis KB, 2005. Low dose radiation induced immunomodulation: effect on macrophages and CD8+ T cells. Int. J. Radiat Biol. 81, 801–812..

    Not in our library10.1080/09553000500531886

  168. 168.

    Pang Q, Wei Q, Xu T, Yuan X, Lopez Guerra JL, Levy LB, Liu Z, Gomez DR, Zhuang Y, Wang LE, Mohan R, Komaki R, Liao Z, 2013. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 85, 1332–1339..

    Not in our library10.1016/j.ijrobp.2012.10.011

  169. 169.

    Pateras IS, Havaki S, Nikitopoulou X, Vougas K, Townsend PA, Panayiotidis MI, Georgakilas AG, Gorgoulis VG, 2015. The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where. Pharmacol. Ther. 154, 36–56..

    Not in our library10.1016/j.pharmthera.2015.06.011

  170. 170.

    Pavlopoulou A, Bagos PG, Koutsandrea V, Georgakilas AG, 2017. Molecular determinants of radiosensitivity in normal and tumor tissue: A bioinformatic approach. Cancer Lett. 403, 37–47..

    Not in our library10.1016/j.canlet.2017.05.023

  171. 171.

    Pavlopoulou A, Karaca E, Balestrazzi A, Georgakilas AG, 2019. In silico phylogenetic and structural analyses of plant endogenous danger signaling molecules upon stress. Oxid Med Cell Longev 2019, 8683054..

    Not in our library10.1155/2019/8683054

  172. 172.

    Persa E, Balogh A, Safrany G, Lumniczky K, 2015. The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett. 368, 252–261..

    Not in our library10.1016/j.canlet.2015.03.003

  173. 173.

    Persa E, Szatmari T, Safrany G, Lumniczky K, 2018. In vivo irradiation of mice induces activation of dendritic cells. Int. J. Mol. Sci. 19.

    Not in our library10.3390/ijms19082391

  174. 174.

    Pouget JP, Georgakilas AG, Ravanat JL, 2018. Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis. Antioxid. Redox Signal. 29, 1447–1487..

    Not in our library10.1089/ars.2017.7267

  175. 175.

    Prasad AV, Mohan N, Chandrasekar B, Meltz ML, 1995. Induction of transcription of “immediate early genes” by low-dose ionizing radiation. Radiat. Res. 143, 263–272.

    Not in our library

  176. 176.

    Pratesi N, Mangoni M, Mancini I, Paiar F, Simi L, Livi L, Cassani S, Buglione M, Grisanti S, Almici C, Polli C, Saieva C, Magrini SM, Biti G, Pazzagli M, Orlando C, 2011. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother. Oncol. 99, 356–361..

    Not in our library10.1016/j.radonc.2011.05.062

  177. 177.

    Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X, 2014. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clin. Pharmacol. Ther. 96, 609–615..

    Not in our library10.1038/clpt.2014.154

  178. 178.

    Quarmby S, Fakhoury H, Levine E, Barber J, Wylie J, Hajeer AH, West C, Stewart A, Magee B, Kumar S, 2003. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int. J. Radiat Biol. 79, 137–143.

    Not in our library

  179. 179.

    Rabbani ZN, Mi J, Zhang Y, Delong M, Jackson IL, Fleckenstein K, Salahuddin FK, Zhang X, Clary B, Anscher MS, Vujaskovic Z, 2010. Hypoxia inducible factor 1alpha signaling in fractionated radiation-induced lung injury: role of oxidative stress and tissue hypoxia. Radiat. Res. 173, 165–174..

    Not in our library10.1667/rr1816.1

  180. 180.

    Radiation, United Nations Scientific Committee on the Effects of Atomic 2008. Effects of Ionizing Radiation, United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) 2006 Report, Volume I.

    Not in our library

  181. 181.

    Radiation, United Nations Scientific Committee on the Effects of Atomic 1972. Ionizing Radiation, Levels and Effects, United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) 1972 Report.

    Not in our library

  182. 182.

    Radiation, United Nations Scientific Committee on the Effects of Atomic 2014. Sources, Effects and Risks of Ionizing Radiation, United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) 2013 Report, Volume II.

    Not in our library

  183. 183.

    Rastogi S, Boylan M, Wright EG, Coates PJ, 2013. Interactions of apoptotic cells with macrophages in radiation-induced bystander signaling. Radiat. Res. 179, 135–145..

    Not in our library10.1667/rr2969.1

  184. 184.

    Ratikan JA, Micewicz ED, Xie MW, Schaue D, 2015. Radiation takes its Toll. Cancer Lett. 368, 238–245..

    Not in our library10.1016/j.canlet.2015.03.031

  185. 185.

    Rees GS, Daniel CP, Morris SD, Whitehouse CA, Binks K, MacGregor DH, Tawn EJ, 2004. Occupational exposure to ionizing radiation has no effect on T- and B-cell total counts or percentages of helper, cytotoxic and activated T-cell subsets in the peripheral circulation of male radiation workers. Int. J. Radiat Biol. 80, 493–498..

    Not in our library10.1080/09553000410001725099

  186. 186.

    Rodel F, Frey B, Gaipl U, Keilholz L, Fournier C, Manda K, Schollnberger H, Hildebrandt G, Rodel C, 2012. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application. Curr. Med. Chem. 19, 1741–1750..

    Not in our library10.2174/092986712800099866

  187. 187.

    Rodel F, Frey B, Multhoff G, Gaipl U, 2015. Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett. 356, 105–113..

    Not in our library10.1016/j.canlet.2013.09.015

  188. 188.

    Rodel F, Hantschel M, Hildebrandt G, Schultze-Mosgau S, Rodel C, Herrmann M, Sauer R, Voll RE, 2004. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa B (NF-kappaB) in EA.hy.926 endothelial cells after low-dose X-irradiation. Int. J. Radiat Biol. 80, 115–123..

    Not in our library10.1080/09553000310001654701

  189. 189.

    Roedel F, Kley N, Beuscher HU, Hildebrandt G, Keilholz L, Kern P, Voll R, Herrmann M, Sauer R, 2002. Anti-inflammatory effect of low-dose X-irradiation and the involvement of a TGF-beta1-induced down-regulation of leukocyte/endothelial cell adhesion. Int. J. Radiat Biol. 78, 711–719..

    Not in our library10.1080/09553000210137671

  190. 190.

    Ron E, Brenner A, 2010. Non-malignant thyroid diseases after a wide range of radiation exposures. Radiat. Res. 174, 877–888..

    Not in our library10.1667/rr1953.1

  191. 191.

    Rothkamm K, Balroop S, Shekhdar J, Fernie P, Goh V, 2007. Leukocyte DNA damage after multi-detector row CT: a quantitative biomarker of low-level radiation exposure. Radiology 242, 244–251..

    Not in our library10.1148/radiol.2421060171

  192. 192.

    Rothkamm K, Lobrich M, 2003. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci U S A 100, 5057–5062..

    Not in our library10.1073/pnas.0830918100

  193. 193.

    Rube CE, Wilfert F, Palm J, Konig J, Burdak-Rothkamm S, Liu L, Schuck A, Willich N, Rube C, 2004. Irradiation induces a biphasic expression of pro-inflammatory cytokines in the lung. Strahlenther. Onkol. 180, 442–448..

    Not in our library10.1007/s00066-004-1265-7

  194. 194.

    Ruhle PF, Wunderlich R, Deloch L, Fournier C, Maier A, Klein G, Fietkau R, Gaipl US, Frey B, 2017. Modulation of the peripheral immune system after low-dose radon spa therapy: Detailed longitudinal immune monitoring of patients within the RAD-ON01 study. Autoimmunity 50, 133–140..

    Not in our library10.1080/08916934.2017.1284819

  195. 195.

    Rybkina VL, Azizova TV, Scherthan H, Meineke V, Doerr H, Adamova GV, Teplyakova OV, Osovets SV, Bannikova MV, Zurochka AV, 2014. Expression of blood serum proteins and lymphocyte differentiation clusters after chronic occupational exposure to ionizing radiation. Radiat. Environ. Biophys. 53, 659–670..

    Not in our library10.1007/s00411-014-0556-3

  196. 196.

    Saenko AS, Zamulaeva IA, Smirnova SG, Orlova NV, Selivanova EI, Matveeva NP, Kaplan MA, Nugis VY, Nadezhina NM, Tsyb AF, 2000. Determination of somatic mutant frequencies at glycophorin A and T-cell receptor loci for biodosimetry of acute and prolonged irradiation. Appl. Radiat. Isot. 52, 1145–1148..

    Not in our library10.1016/s0969-8043(00)00061-0

  197. 197.

    Saenko V, Ivanov V, Tsyb A, Bogdanova T, Tronko M, Demidchik Y, Yamashita S, 2011. The Chernobyl accident and its consequences. Clin. Oncol. (R Coll Radiol) 23, 234–243..

    Not in our library10.1016/j.clon.2011.01.502

  198. 198.

    Sambani C, Thomou H, Kitsiou P, 1996. Stimulatory effect of low dose X-irradiation on the expression of the human T lymphocyte CD2 surface antigen. Int. J. Radiat Biol. 70, 711–717..

    Not in our library10.1080/095530096144608

  199. 199.

    Santana MA, Esquivel-Guadarrama F, 2006. Cell biology of T cell activation and differentiation. Int. Rev. Cytol. 250, 217–274..

    Not in our library10.1016/s0074-7696(06)50006-3

  200. 200.

    Schaue D, 2017. A century of radiation therapy and adaptive immunity. Front. Immunol. 8, 431..

    Not in our library10.3389/fimmu.2017.00431

  201. 201.

    Schaue D, Marples B, Trott KR, 2002. The effects of low-dose X-irradiation on the oxidative burst in stimulated macrophages. Int. J. Radiat Biol. 78, 567–576..

    Not in our library10.1080/09553000210126457

  202. 202.

    Seibold P, Behrens S, Schmezer P, Helmbold I, Barnett G, Coles C, Yarnold J, Talbot CJ, Imai T, Azria D, Koch CA, Dunning AM, Burnet N, Bliss JM, Symonds RP, Rattay T, Suga T, Kerns SL, Bourgier C, Vallis KA, Sautter-Bihl ML, Classen J, Debus J, Schnabel T, Rosenstein BS, Wenz F, West CM, Popanda O, Chang-Claude J, 2015. XRCC1 polymorphism associated with late toxicity after radiation therapy in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 92, 1084–1092..

    Not in our library10.1016/j.ijrobp.2015.04.011

  203. 203.

    Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Classen J, Delmastro E, Dunning AM, Elliott RM, Fachal L, Farcy-Jacquet MP, Gabriele P, Garibaldi E, Gomez-Caamano A, Gutierrez-Enriquez S, Higginson DS, Johnson K, Lobato-Busto R, Molla M, Muller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruysscher D, De Santis MC, Schafer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weissenberger C, West CML, Chang-Claude Requite consortium J, 2019. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother. Oncol. 138, 59–67..

    Not in our library10.1016/j.radonc.2019.04.034

  204. 204.

    Sheikh Sajjadieh MR, Kuznetsova LV, Bojenko V, 2012. Cytokine status in Ukrainian children with irritable bowel syndrome residing in a radioactive contaminated area. Iran. J. Immunol. 9, 248–253.

    Not in our library10.22034/iji.2012.16878

  205. 205.

    Shin SC, Lee KM, Kang YM, Kim K, Kim CS, Yang KH, Jin YW, Kim CS, Kim HS, 2010. Alteration of cytokine profiles in mice exposed to chronic low-dose ionizing radiation. Biochem. Biophys. Res. Commun. 397, 644–649..

    Not in our library10.1016/j.bbrc.2010.05.121

  206. 206.

    Siva S, Lobachevsky P, MacManus MP, Kron T, Moller A, Lobb RJ, Ventura J, Best N, Smith J, Ball D, Martin OA, 2016. Radiotherapy for non-small cell lung cancer induces DNA damage response in both irradiated and out-of-field normal tissues. Clin. Cancer Res. 22, 4817–4826..

    Not in our library10.1158/1078-0432.ccr-16-0138

  207. 207.
    A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer. · 2014
    Not checked
  208. 208.

    Siva S, MacManus MP, Martin RF, Martin OA, 2015. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 356, 82–90..

    Not in our library10.1016/j.canlet.2013.09.018

  209. 209.
    Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. · 2012
    Not checked
  210. 210.

    Sonn CH, Choi JR, Kim TJ, Yu YB, Kim K, Shin SC, Park GH, Shirakawa T, Kim HS, Lee KM, 2012. Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2. J. Radiat. Res. 53, 823–829..

    Not in our library10.1093/jrr/rrs037

  211. 211.

    Sprung CN, Forrester HB, Siva S, Martin OA, 2015. Immunological markers that predict radiation toxicity. Cancer Lett. 368, 191–197..

    Not in our library10.1016/j.canlet.2015.01.045

  212. 212.

    Swanson GP, Jhavar SG, Hammonds K, 2020. The effect of pelvic radiation alone on lymphocyte subgroups. Clin Transl Radiat Oncol 23, 100–102..

    Not in our library10.1016/j.ctro.2020.05.010

  213. 213.

    Takahashi T, Fujimori K, Simon SL, Bechtner G, Edwards R, Trott KR, 1999. Thyroid nodules, thyroid function and dietary iodine in the Marshall islands. Int. J. Epidemiol. 28, 742–749..

    Not in our library10.1093/ije/28.4.742

  214. 214.

    Talbot CJ, Tanteles GA, Barnett GC, Burnet NG, Chang-Claude J, Coles CE, Davidson S, Dunning AM, Mills J, Murray RJ, Popanda O, Seibold P, West CM, Yarnold JR, Symonds RP, 2012. A replicated association between polymorphisms near TNFalpha and risk for adverse reactions to radiotherapy. Br. J. Cancer 107, 748–753..

    Not in our library10.1038/bjc.2012.290

  215. 215.

    Tang Y, Liu B, Li J, Wu H, Yang J, Zhou X, Yi M, Li Q, Yu S, Yuan X, 2016. Genetic variants in PI3K/AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy. Cancer Med 5, 24–32..

    Not in our library10.1002/cam4.564

  216. 216.

    Tang Y, Yang L, Qin W, Yi M, Liu B, Yuan X, 2019. Validation study of the association between genetic variant of IL4 and severe radiation pneumonitis in lung cancer patients treated with radiation therapy. Radiother. Oncol. 141, 86–94..

    Not in our library10.1016/j.radonc.2019.09.002

  217. 217.

    Tang Y, Yang L, Qin W, Yi MX, Liu B, Yuan X, 2020. Impact of genetic variant of HIPK2 on the risk of severe radiation pneumonitis in lung cancer patients treated with radiation therapy. Radiat Oncol 15, 9..

    Not in our library10.1186/s13014-019-1456-0

  218. 218.

    Terrazzino S, La Mattina P, Gambaro G, Masini L, Franco P, Canonico PL, Genazzani AA, Krengli M, 2012. Common variants of GSTP1, GSTA1, and TGFbeta1 are associated with the risk of radiation-induced fibrosis in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 83, 504–511..

    Not in our library10.1016/j.ijrobp.2011.06.2012

  219. 219.
    Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects · 2019
    Not checked
  220. 220.

    Turner MD, Nedjai B, Hurst T, Pennington DJ, 2014. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta, Rev. Cancer 1843, 2563–2582..

    Not in our library10.1016/j.bbamcr.2014.05.014

  221. 221.

    Valledor AF, Comalada M, Santamaria-Babi LF, Lloberas J, Celada A, 2010. Macrophage proinflammatory activation and deactivation: a question of balance. Adv. Immunol. 108, 1–20..

    Not in our library10.1016/b978-0-12-380995-7.00001-x

  222. 222.

    Venkatesh GH, Manjunath VB, Mumbrekar KD, Negi H, Fernandes DJ, Sharan K, Banerjee S, Bola Sadashiva SR, 2014. Polymorphisms in radio-responsive genes and its association with acute toxicity among head and neck cancer patients. PLoS One 9..

    Not in our library10.1371/journal.pone.0089079

  223. 223.

    Voets AM, Oberije C, Struijk RB, Reymen B, De Ruyck K, Thierens H, Vandecasteele K, De Neve W, Houben R, De Ruysscher D, Smeets HJ, Lambin P, 2012. No association between TGF-beta1 polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients. Radiother. Oncol. 105, 296–298..

    Not in our library10.1016/j.radonc.2012.09.016

  224. 224.

    Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I, 1997. Immunosuppressive effects of apoptotic cells. Nature 390, 350–351..

    Not in our library10.1038/37022

  225. 225.

    Vujaskovic Z, Anscher MS, Feng QF, Rabbani ZN, Amin K, Samulski TS, Dewhirst MW, Haroon ZA, 2001. Radiation-induced hypoxia may perpetuate late normal tissue injury. Int. J. Radiat. Oncol. Biol. Phys. 50, 851–855..

    Not in our library10.1016/s0360-3016(01)01593-0

  226. 226.

    Vykhovanets EV, Chernyshov VP, Slukvin, Antipkin YG, Vasyuk A, Colos V, 2000. Analysis of blood lymphocyte subsets in children living around Chernobyl exposed long-term to low doses of cesium-137 and various doses of iodine-131. Radiat. Res. 153, 760–772..

    Not in our library10.1667/0033-7587(2000)153[0760:aoblsi]2.0.co;2

  227. 227.

    Wang L, Bi N, 2010. TGF-beta1 gene polymorphisms for anticipating radiation-induced pneumonitis in non-small-cell lung cancer: different ethnic association. J. Clin. Oncol. 28, e621–e622..

    Not in our library10.1200/jco.2010.31.0458

  228. 228.

    Wen J, Liu H, Wang L, Wang X, Gu N, Liu Z, Xu T, Gomez DR, Komaki R, Liao Z, Wei Q, 2018. Potentially functional variants of ATG16L2 Predict radiation pneumonitis and outcomes in patients with non-small cell lung cancer after definitive radiotherapy. J. Thorac Oncol. 13, 660–675..

    Not in our library10.1016/j.jtho.2018.01.028

  229. 229.

    Wen J, Liu H, Wang Q, Liu Z, Li Y, Xiong H, Xu T, Li P, Wang LE, Gomez DR, Mohan R, Komaki R, Liao Z, Wei Q, 2014. Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Eur. J. Cancer 50, 1706–1716..

    Not in our library10.1016/j.ejca.2014.03.008

  230. 230.

    West C, Azria D, Chang-Claude J, Davidson S, Lambin P, Rosenstein B, De Ruysscher D, Talbot C, Thierens H, Valdagni R, Vega A, Yuille M, 2014. The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors. Clin. Oncol. (R Coll Radiol) 26, 739–742..

    Not in our library10.1016/j.clon.2014.09.008

  231. 231.

    West CM, Barnett GC, 2011. Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med. 3, 52..

    Not in our library10.1186/gm268

  232. 232.

    Woodward WA, Debeb BG, Xu W, Buchholz TA, 2010. Overcoming radiation resistance in inflammatory breast cancer. Cancer 116, 2840–2845..

    Not in our library10.1002/cncr.25173

  233. 233.

    Wunderlich R, Ernst A, Rodel F, Fietkau R, Ott O, Lauber K, Frey B, Gaipl US, 2015. Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin. Exp. Immunol. 179, 50–61..

    Not in our library10.1111/cei.12344

  234. 234.

    Wunderlich R, Ruhle PF, Deloch L, Rodel F, Fietkau R, Gaipl US, Frey B, 2019. Ionizing radiation reduces the capacity of activated macrophages to induce T-cell proliferation, but does not trigger dendritic cell-mediated non-targeted effects. Int. J. Radiat Biol. 95, 33–43..

    Not in our library10.1080/09553002.2018.1490037

  235. 235.

    Wynn TA, Chawla A, Pollard JW, 2013. Macrophage biology in development, homeostasis and disease. Nature 496, 445–455..

    Not in our library10.1038/nature12034

  236. 236.

    Xiong H, Liao Z, Liu Z, Xu T, Wang Q, Liu H, Komaki R, Gomez D, Wang LE, Wei Q, 2013. ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 85, 1066–1073..

    Not in our library10.1016/j.ijrobp.2012.09.024

  237. 237.

    Xu L, Jiang J, Li Y, Zhang L, Li Z, Xian J, Jiang C, Diao Y, Su X, Xu H, Zhang Y, Zhang T, Yang Z, Tan B, Li H, 2019. Genetic variants of SP-D confer susceptibility to radiation pneumonitis in lung cancer patients undergoing thoracic radiation therapy. Cancer Med. 8, 2599–2611..

    Not in our library10.1002/cam4.2088

  238. 238.

    Xu Y, Greenstock CL, Trivedi A, Mitchel RE, 1996. Occupational levels of radiation exposure induce surface expression of interleukin-2 receptors in stimulated human peripheral blood lymphocytes. Radiat. Environ. Biophys. 35, 89–93..

    Not in our library10.1007/bf02434030

  239. 239.

    Yang G, Kong Q, Wang G, Jin H, Zhou L, Yu D, Niu C, Han W, Li W, Cui J, 2014. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother. Radiopharm. 29, 428–434..

    Not in our library10.1089/cbr.2014.1702

  240. 240.

    Yang J, Xu T, Gomez DR, Yuan X, Nguyen QN, Jeter M, Song Y, Hahn S, Liao Z, 2017. Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer. Oncotarget 8, 43080–43090..

    Not in our library10.18632/oncotarget.17904

  241. 241.

    Yang M, Zhang L, Bi N, Ji W, Tan W, Zhao L, Yu D, Wu C, Wang L, Lin D, 2011. Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 79, 1402–1407..

    Not in our library10.1016/j.ijrobp.2009.12.042

  242. 242.

    Yang Z, Liu Z, 2019. Potentially functional variants of autophagy-related genes are associated with the efficacy and toxicity of radiotherapy in patients with nasopharyngeal carcinoma. Mol. Genet. Genomic Med. 7.

    Not in our library10.1002/mgg3.1030

  243. 243.

    Yin M, Liao Z, Huang YJ, Liu Z, Yuan X, Gomez D, Wang LE, Wei Q, 2011a. Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy. PLoS One 6..

    Not in our library10.1371/journal.pone.0020055

  244. 244.

    Yin M, Liao Z, Liu Z, Wang LE, Gomez D, Komaki R, Wei Q, 2011b. Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 81, e67–e73..

    Not in our library10.1016/j.ijrobp.2010.11.079

  245. 245.

    Yin M, Liao Z, Liu Z, Wang LE, O’Reilly M, Gomez D, Li M, Komaki R, Wei Q, 2012a. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer 118, 528–535..

    Not in our library10.1002/cncr.26214

  246. 246.

    Yin M, Liao Z, Yuan X, Guan X, O’Reilly MS, Welsh J, Wang LE, Wei Q, 2012b. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci. 103, 945–950..

    Not in our library10.1111/j.1349-7006.2012.02229.x

  247. 247.

    Yin X, Mason J, Lobachevsky PN, Munforte L, Selbie L, Ball DL, Martin RF, Leong T, Siva S, Martin OA, 2019. Radiation therapy modulates DNA repair efficiency in peripheral blood mononuclear cells of patients with non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 103, 521–531..

    Not in our library10.1016/j.ijrobp.2018.10.001

  248. 248.

    Yoshida K, French B, Yoshida N, Hida A, Ohishi W, Kusunoki Y, 2019. Radiation exposure and longitudinal changes in peripheral monocytes over 50 years: the Adult Health Study of atomic-bomb survivors. Br. J. Haematol. 185, 107–115..

    Not in our library10.1111/bjh.15750

  249. 249.

    Yoshida K, Misumi M, Kubo Y, Yamaoka M, Kyoizumi S, Ohishi W, Hayashi T, Kusunoki Y, 2016. Long-term effects of radiation exposure and metabolic status on telomere length of peripheral blood T cells in atomic bomb survivors. Radiat. Res. 186, 367–376..

    Not in our library10.1667/rr14389.1

  250. 250.

    Yu J, Huang Y, Liu L, Wang J, Yin J, Huang L, Chen S, Li J, Yuan H, Yang G, Liu W, Wang H, Pei Q, Guo C, 2016. Genetic polymorphisms of Wnt/beta-catenin pathway genes are associated with the efficacy and toxicities of radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget 7, 82528–82537..

    Not in our library10.18632/oncotarget.12754

  251. 251.

    Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, Milas L, Wei Q, 2009. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J. Clin. Oncol. 27, 3370–3378..

    Not in our library10.1200/jco.2008.20.6763

  252. 252.

    Zakeri F, Hirobe T, Akbari Noghabi K, 2010. Biological effects of low-dose ionizing radiation exposure on interventional cardiologists. Occup Med (Lond) 60, 464–469..

    Not in our library10.1093/occmed/kqq062

  253. 253.

    Zhang L, Yang M, Bi N, Fang M, Sun T, Ji W, Tan W, Zhao L, Yu D, Lin D, Wang L, 2010. ATM polymorphisms are associated with risk of radiation-induced pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 77, 1360–1368..

    Not in our library10.1016/j.ijrobp.2009.07.1675

  254. 254.

    Zhang Y, Liu Z, Wang M, Tian H, Su K, Cui J, Dong L, Han F, 2016. Single nucleotide polymorphism rs1801516 in ataxia telangiectasia-mutated gene predicts late fibrosis in cancer patients after radiotherapy: A PRISMA-compliant systematic review and meta-analysis. Med. (Baltimore) 95..

    Not in our library10.1097/md.0000000000003267

  255. 255.

    Zhao L, Pu X, Ye Y, Lu C, Chang JY, Wu X, 2016. Association between genetic variants in DNA double-strand break repair pathways and risk of radiation therapy-induced pneumonitis and esophagitis in non-small cell lung cancer. Cancers (Basel) 8..

    Not in our library10.3390/cancers8020023

  256. 256.

    Zhu ML, Wang M, Shi TY, Li QX, Xi P, Xia KQ, Zheng L, Wei QY, 2013. No association between TGFB1 polymorphisms and late radiotherapy toxicity: a meta-analysis. PLoS One 8..

    Not in our library10.1371/journal.pone.0076964

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.